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Abstract
Duchenne muscular dystrophy (DMD) is a progressive muscular degenerative disease
affecting 1 in 3,500 boys. Cardiomyopathy is observed in 95% of patients aged 18 and older,
accounting for 30% of deaths. While innovative treatments have been employed to curb
symptoms in skeletal muscle, few show success in the heart, and no cure for DMD exists.
Recently, regenerative therapy using cardiac stem cells (CSCs) has shown very promising
results, but efficacy in DMD remains undetermined. This dissertation sought to provide
preliminary insight into the effects of murine Sca-1+ CSC therapy. Three-dimensional
echocardiography was validated and used to gauge cardiomyopathy in the mdx:utrn-/- mouse
model. CSCs were isolated from healthy mice and displayed differentiation potential. They
were implanted into mdx:utrn-/- mice under ultrasound guidance, and showed preliminary
trends towards functional improvement. These results support the notion that stem cells may
be an excellent avenue of therapy that should be further investigated.
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Introduction

Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder
occurring in about 1 in 3500 boys. It is caused by genetic mutations in the dystrophin
gene, which encodes a cytoplasmic protein connecting the cytoskeleton of a muscle fibre
to the surrounding extracellular matrix, providing muscle cell membrane stability1. In the
absence of functional dystrophin, skeletal muscle progressively deteriorates, resulting in a
weakening of voluntary movement. Patients are confined to a wheelchair, subsequently
experiencing reduced strength and endurance in the advanced stages of DMD; they
eventually succumb due to asphyxia brought on by loss of diaphragm function.
Aside from its effects on skeletal muscle, DMD also manifests itself in heart muscle
tissue as a condition called dilated cardiomyopathy2. Although clinical advances and
therapeutic successes have greatly improved the quality of life for patients struggling
with this disease, most are focused on managing the skeletal muscle involvement, and
few directly tackle the problems that occur within the heart; as such, patient death as a
result of cardiomyopathy alone accounts for over 30% of all DMD deaths. To date, no
cure for DMD exists.
These statistics represent a clear and unmet need for novel and innovative treatment
strategies to combat DMD-related cardiomyopathy. This dissertation will provide
background to DMD, related research and therapeutic strategies, and will present the
rationale and preliminary pre-clinical evidence supporting a novel stem cell-based
therapeutic approach.

1.1

The Heart

The circulatory system is a complex group of organs that functions to circulate blood
around the body, delivering necessary oxygen and nutrients, as well as hormones and
immune cells, to the tissues of the body. Importantly, it also plays a crucial role in
maintaining homeostasis, or the physiological balance of an organism3. At the centre of
this system is the heart—a four-chambered pump that provides the force to drive the
blood volume through blood vessels.
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The heart is a fist-sized organ that is divided into the ‘right heart’, which drives
circulation of deoxygenated blood to the lungs, and the ‘left heart’, which drives
oxygenated blood arriving from the heart to the rest of the body. Each of the two halves is
comprised of two chambers—an atrium and a ventricle—which function to pump blood
through rhythmic contraction and relaxation; the former is known as systole, and the
latter as diastole. The chambers are separated by a set of valves, which serve to maintain
unidirectional movement of blood through systole and diastole. Deoxygenated blood
arrives into the right atrium through the superior and anterior vena cava, and is pumped
by the right atrium into the right ventricle through the tricuspid valve during atrial
systole. The right ventricle, in turn, pumps blood through the pulmonary valve to the
lungs in ventricular systole. Blood becomes oxygenated in the lungs, after which it is
brought back to the left atrium of the heart through the pulmonary veins. In a similar
fashion as the right atrium, the left atrium pumps blood to the left ventricle through the
mitral valve during atrial systole. The left ventricle is the largest and strongest chamber
of the heart, as it drives oxygenated blood throughout the entire body. The muscle of the
left ventricle is arranged in a ‘swirling’ pattern that allows it to pump blood very
effectively through the aortic valve and to the rest of the body during ventricular systole.
The dynamics of systolic-diastolic cardiac contraction are controlled by a nervous region
within the heart known as the sinoatrial node (SA node), or the pacemaker. It generates
electrical impulses called action potentials that travel quickly through the muscles of the
heart; the rate at which these are generated will ultimately determine heart rate. The SA
node is located close to the atria, and as such causes them to contract first, in unison,
resulting in atrial systole. Action potentials are then transmitted to a relay point known as
the atrioventricular node, where they are delayed by a matter of milliseconds before being
transmitted through Purkinje fibres, a special type of muscle tissue, to the apex of the
heart and to the ventricular tissue. This results in the ventricles contracting in unison after
the atria, and ensures proper unidirectional blood flow through the heart.

1.1.1

Cardiovascular Disease (CVD)

As the heart is an important and central organ in the body, diseases affecting it are very
debilitating. Despite significant advancements in clinical treatment and patient care,
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cardiovascular disease (CVD) remains the leading cause of death worldwide4. Though its
prevalence is higher in developing countries, the effects of CVD in Western countries
remain substantial. In Canada, it is responsible for 19.7% of total death yearly, second
only to cancer5. As such, it places a heavy burden on the healthcare system and costs the
Canadian economy an estimated $29 billion annually6. As the incidence of CVD
continues to increase, the global death toll is expected to rise to 23.6 million by 20307.
A wide array of conditions are classified under CVD, and these affect the cardiovascular
system in many different ways. They can range from diseases of the blood vessels (e.g.
hypertension, atherosclerosis), which also include conditions affecting the coronary
arteries that supply blood to the heart muscle (coronary artery disease), to diseases of the
heart itself, such as dysregulation of the heartbeat (arrhythmia), inflammatory heart
disease, and cardiomyopathy, or disease of the heart muscle. Each condition is complex
and requires innovative approaches for diagnosis and treatment.

1.1.2

Cardiac Muscle and Cardiomyopathy

Although coronary artery disease remains the single largest contributor to CVD,
conditions affecting the heart muscle, collectively known as the cardiomyopathies, are
also very clinically devastating8. The myocardium, or muscle of the heart, is an
involuntary type of striated muscle that is comprised of cells called cardiomyocytes.
Unlike skeletal muscle, these cells are short and branched, with one cardiomyocyte
connecting to many neighbours through junctions called intercalated disks9. This forms a
network of muscle cells which contract together in order to produce the strong pumping
force necessary to move blood around the body. As with skeletal muscle cells,
cardiomyocytes are surrounded by a specialized cell membrane called the sarcolemma.
Action potentials are transmitted through cardiac muscle by special structures in the
sarcolemma called gap junctions; these are found between neighbouring cells at the
intercalated disks. The sarcolemma contains many ‘L-type’ calcium channels, which
allow calcium ions from the extracellular space to enter the cell and depolarize it,
generating and maintaining action potentials. Despite structural differences at the cellular
level, cardiac muscle contracts much in the same way skeletal muscle does, and as such,
can be described by the actin/myosin sliding filament model. Individual cardiomyocytes
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are surrounded by a layer of connective tissue called the endomysium, which is made up
of fibroblasts and extracellular matrix proteins such as collagen and laminin. Together,
the cells form the myocardium, which itself is lined by two layers: the facet which makes
up the chambers is lined with endocardium, while the outer facet is covered by the dualwalled pericardium. Two major coronary arteries run along either side of the heart, which
supply fresh oxygenated blood to the myocardium.
Cardiomyopathies are defined as structural and functional abnormalities of the
myocardium associated with dysfunction10. They present serious clinical concern due to
their prevalence and high likelihood for patients to experience heart failure in later stages
as a result of arrhythmia and sudden cardiac death11. The diseases classified as
cardiomyopathies are wide-ranging and heterogeneous, involving organs other than the
heart, and have many intrinsic and extrinsic contributing factors. In fact, their complexity
necessitates a distinct nosology and nomenclature12. However, for the past 50 years, they
have been divided into five general categories: dilated cardiomyopathy, hypertrophic
cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic cardiomyopathy, and left
ventricular non-compaction13.

1.1.3

Dilated Cardiomyopathy

Dilated cardiomyopathy is the most common type of cardiomyopathy11,13. It may be
caused by viral infection and autoimmunity, but in most cases, it is genetically inherited
from the parents. The typical age of occurrence is 20 to 60, and prevalence is different
among the sexes, with men more likely to have it than women. Prototypically, it involves
a combined thinning and stretching (dilatation) of the myocardium that mainly affects the
left ventricle; this causes the chamber to enlarge, and results in substantially impaired
contractile function10. This leaves patients at high risk of heart failure in advanced stages,
especially as a localized disease can spread to the other chambers of the heart over time.
Some of the symptoms include swelling in the lower extremities, fatigue, shortness of
breath, and patients with dilated cardiomyopathy may also exhibit arrhythmia and heart
valve problems8. Due to its prevalence and involvement with other diseases, it has
received much research interest in the last decade.
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1.2

The Muscular Dystrophies

The muscular dystrophies are a family of neuromuscular diseases characterized by
progressive muscular degeneration leading to weakness in voluntary and involuntary
contraction. Over 40 different types of muscular dystrophy have been classified to date14,
and these can affect the skeletal muscle, diaphragm muscle, eyes, and brain15. While the
term is used to classify a wide range of conditions affecting multiple parts of the body,
the most common and clinically relevant forms of muscular dystrophy share a similar
molecular basis, namely the dystrophin protein. Widely-known as one of the largest
human proteins at 427 kilodaltons16, dystrophin is a cytoplasmic protein located at the
muscular sarcolemmal membrane. It is the archetype in a family of related muscleassociated proteins known as the dystrophin-associated glycoproteins; these include the
dystroglycans, dystrobrevins, sarcoglycans, and syntrophins17. Together, these proteins
form a complex at the sarcolemma known as the dystrophin-associated glycoprotein
complex (DAG) or the costamere. This crucial membrane-spanning complex serves to
link the cytoskeletal actin filaments of a muscle fibre to collagen in the fibrous
endomysium outside the sarcolemma, providing stability, deformability, and muscle
integrity during contraction1,18. Many of the proteins also have roles in maintaining the
integrity of neuromuscular junctions. Dystrophin itself is found in the cytoplasmic
compartment, and serves as the linkage between actin and the intercellular domain of the
dystroglycan complex (Figure 1.1).

6

Figure 1.1 Dystrophin-associated glycoprotein complex (DAG). Dystrophin serves to
bind the F-actin cytoskeleton to the extracellular matrix (basal lamina) through the DAG.
Many proteins, including dystroglycans, dystrobrevins, sarcoglycans, and syntrophins,
are associated with and offer support to the DAG; for ease of interpretation, they are
omitted here. The dystrophin protein has three domains: the actin-binding domain (1), the
rod/spring domain (2), and the C-terminal domain (3) which binds dystroglycan.
It is evident that dystrophin forms an integral part of the complex; indeed, changes in its
protein structure ultimately lead to a loss of cellular membrane integrity. A lack of
functional linkage between the sarcolemma and the actin cytoskeleton leads to shearing
during muscle contraction9. Sarcolemmal ion channels are compromised, causing an
abnormal influx of extracellular calcium into myocytes19,20, and overproduction of nitric
oxide21. This results in the activation of calpain proteases which degrade troponin I,
compromising contractile ability22. Furthermore, it causes an influx of water into
mitochondria, which eventually shear; the cellular stress resulting from this causes more
calcium ions to flow into the myocyte. It also results in an increased production of
reactive oxygen species which stimulate the NF-κB signalling pathway responsible for
the expression of pro-inflammatory cytokines, stimulating an immune response at the
site19,23,24. Macrophages infiltrate afflicted tissue, resulting in inflammation, further
sarcolemmal instability, and loss of muscle fibres as the rate of necrosis exceeds that of
regeneration. Although cardiac myoblasts regenerate cardiomyocytes efficiently in the
very early stages of the disease, continued shearing and inflammation soon cause the
demand for new cardiomyocytes to surpass the regenerative capacity of the tissue. A
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large number of fibroblasts and myofibroblasts are recruited along with macrophages to
the injured site, where they begin to produce collagenous scar tissue to fill the void left
by dead cardiomyocytes25,26. The persistence of fibroblasts results in the production of a
large quantity of extracellular matrix, which unlike the myocardium, is not contractile. A
combination of increased wall stress, increased demand for oxygen, continued myocyte
death, and replacement fibrosis, results in a vicious cycle of muscular deterioration. As
the muscle is continuously and progressively damaged over time, excess fibrosis results
in loss of contractile function, the hallmark of the muscular dystrophies27.
The bases of dystrophin protein malformations lie at the genetic level, and are caused by
inherited mutations. The gene encoding dystrophin is the largest gene within the human
genome—found at locus Xp21 on the X-chromosome, it spans over 2.5 megabases and is
comprised of 79 exons, or coding regions of DNA18. Its large size makes it prone to
genetic mutation; the mutated allele of dystrophin is recessive, meaning that a healthy or
dominant allele on the opposite chromosome will be preferentially expressed. Its Xlinkage explains why females are most likely to be carriers, as a functional dystrophin
allele on one X chromosome will compensate for a mutated allele on the other. However,
if a mother passes the mutant allele on to her son, he will be affected as males only have a
single copy of the X-chromosome, termed hemizygosity.
Mutations affecting dystrophin vary in type and extent. Generally, the causes of these
mutations are deletions within the internal regions of the gene, which code for the central,
spring-like domain of the protein28. When these deletions are ‘in-frame’, meaning that
downstream regions of the coding sequence are unaffected, a mostly working dystrophin
is generated. Although it is shortened, this protein still has the ability to function due to
the unaffected binding domains found on either side of the protein—they will still link
the cytoskeleton to the extracellular matrix, albeit with reduced efficiency. This results in
a condition known as Becker muscular dystrophy (BMD). It is the second-most common
form of muscular dystrophy, wherein patients exhibit a relatively mild phenotype with
late onset and long life expectancy. Patients with BMD are largely ambulatory and often
live into their fifties and sixties1.
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1.2.1

Duchenne Muscular Dystrophy (DMD)

The most common and severe form of muscular dystrophy is known as Duchenne
muscular dystrophy (DMD). It affects around 1 in 3500 boys, with onset in early
childhood1. As opposed to the mild phenotype of BMD, DMD is characterized by a
progressive and severe muscular degeneration. Patients require walking supports very
early in life, are confined to a wheelchair by age 12, and subsequently experience
debilitating reductions in strength and endurance in the advanced stages of the disease;
they eventually succumb to asphyxia brought on by loss of diaphragm function27.
Whereas in BMD the dystrophin protein is merely truncated, DMD is caused by a
completely non-functional dystrophin. A nonsense mutation, or a mutation that
introduces a premature stop codon in the sequence, halts dystrophin protein synthesis
prematurely—ribosomes are essentially unable to read past this stop signal29. The result
is a cut-off dystrophin protein containing only a single binding domain; the absence of
either the C-terminal or N-terminal domain effectively abolishes the possibility for
linkage between the cytoskeleton and the extracellular matrix within muscle cells.
As muscle becomes damaged, it releases creatine kinase, an enzyme found in low levels
in healthy individuals, into the bloodstream; this has been the classic diagnostic
indication of DMD-related muscle degeneration9,30. If left untreated, patients have a life
expectancy of under 30 years. This is largely caused by DMD’s involvement in all
muscle tissue types of the body, including skeletal, cardiac, and smooth muscle. It also
has significant osseous involvement, characterized by disuse osteopenia31.

1.2.2

Cardiac Muscle Manifestations of DMD

Aside from its effects in skeletal muscle, DMD has substantial involvement in the heart,
where it manifests itself as dilated cardiomyopathy2. While DMD has classically been
considered a skeletal muscle pathology that also includes the diaphragm musculature,
improvements in palliative care now extend the lifespan of patients such that clinically
relevant cardiomyopathy is observed in over 95% of affected individuals32. Around 25%
of children under the age of 6 suffering from DMD exhibit discernible cardiac
involvement, which becomes a clinically relevant deterioration of cardiac function
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around 10 years of age; by 18 years of age, nearly all patients exhibit
cardiomyopathy33,34. In the clinic, cardiac involvement is most often detected through
electrocardiography (the analysis of the electrical activity within the heart) and
echocardiography (the assessment of heart function by ultrasound imaging), but may also
be diagnosed through x-ray computed tomography (CT), cardiac magnetic resonance
imaging (MRI), and radionuclide imaging25,34–37.
The fibrotic region characteristic of DMD gradually expands along the walls of the heart,
causing them to become thinner and lose contractility. This results in a dilated
cardiomyopathy characterized by an enlarged, dysfunctional left ventricle, compromised
systolic function, and mitral valve regurgitation; this causes decreased cardiac output and
hemodynamic decompensation25,28. Cardiomyopathy is also be accompanied by
conduction abnormalities, arrhythmias, and tachycardia when patients enter their late
twenties37. Unfortunately, the cardiac aspect of DMD is largely asymptomatic until heart
function is severely hindered38.
Research over the last decade has largely and appropriately focused on developing
treatments to address the skeletal muscle manifestations of DMD, allowing patients to
experience a much longer life expectancy and improved quality of life than ever before32.
However, DMD-related cardiomyopathy has received less clinical interest, and mortality
due to cardiomyopathy continues to represent over 30% of all DMD-related deaths,
causing serious concern39.
As it stands, the current paradigm of DMD is that a combination of ischemia,
inflammation, and fibrosis, all acting together and building upon the effects of the other,
are responsible for the devastating condition seen in patients40,41. There is a clear and
unmet need for therapies to curb the effects of this vicious cycle, and these need to be
explored first in a pre-clinical model, before an effective treatment can be brought to
clinical trial.
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1.3

Pre-Clinical Models of DMD

Animal models have played a crucial and indispensable role in pre-clinical therapeutic
research. They provide an accurate and dynamic model of human disorders, and can offer
an insight into the mechanics of disease that is simply unattainable with standard in vitro
techniques. The optimal animal model is one that closely resembles the human condition,
and which will also respond in the same way as humans to potential treatments. Further
factors, such as size, gestation period, life expectancy, and cost of upkeep, must also be
taken into account.
For the purposes of DMD research, several mammalian models have been used. Perhaps
most appropriate are the canine and feline models. The former, termed canine X-linked
muscular dystrophy (cxmd), contains a premature stop codon much like in humans, and
exhibits a rapidly progressing muscular phenotype, as well as significant left ventricular
dilation and decreased systolic function42. However, aside from their large size and costly
upkeep, the cxmd dogs show high variation in disease severity among littermates, and
cardiac involvement appears only after several years30. The second large animal model is
the hypertrophic feline muscular dystrophy (hfmd) cat, which possesses mutations in the
dystrophin gene and elevated creatine kinase levels. Nevertheless, this model is largely
characterized by a hypertrophic muscle phenotype, and shows little sign of fibrosis and
cardiac involvement18,28,30. This is thought to arise as a result of the feline physiology,
and as such, the hfmd cat provides a relatively poor representation of the human
condition. Furthermore, the large size of both of these models presents limitations in
terms of obtaining and administering sufficient amounts of therapeutic agents under
study, which is particularly problematic for research using biological agents.

1.3.1

Mouse Models of DMD

Considerable research employs rodent models, specifically mice, due to the availability
of a wide range of inbred, genetically modified, and transgenic strains that accurately
represent many human diseases43. As such, DMD has largely been characterized in mice
due to their short life cycle, high breeding rate, and similarity to humans in regards to
genetic orthology and disease symptoms38,44. Moreover, their susceptibility to effective
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genetic modification has allowed the generation of a multitude of different single- and
double-knockout DMD strains, including knockouts for dystrophin (mdx), utrophin
(mdx:utrn-/-), MyoD (mdx:myod-/-), dystrobrevin (mdx:adbn-/-), α7-integrin
(mdx:itga7-/-), parvalbumin (mdx:pv-/-), and desmin (mdx:des-/-)30,45,46.
By far, the most widely used model of DMD is the dystrophin-knockout mouse known as
‘X chromosome-linked muscular dystrophy’ or mdx mouse, which genotypically mirrors
the human condition. Much like in patients, this is induced by a nonsense mutation in the
dystrophin gene on the X chromosome, halting protein synthesis prematurely47,48. Thus,
mdx mice have found great applicability in skeletal muscle studies. Aged mdx mice have
also been shown to exhibit features of cardiomyopathy observed in patients, including
compromised growth factor response41. However, this model only shows mild, nonprogressive skeletal pathology, with no signs of cardiomyopathy before 10 months of
age49, at which point it varies widely in severity between animals50. These factors limit
this strain’s applicability to time-sensitive cardiac functional studies. The relatively mild
phenotype of mdx mice is attributed to up-regulation of utrophin, a protein homolog of
dystrophin which can substitute, at least in part, for dystrophin in the dystrophinassociated glycoprotein complex51. In comparison, the dystrophin/utrophin doubleknockout mouse model (mdx:utrn-/-) exhibits severe progressive skeletal muscle
degeneration as well as cardiac pathology between 8-10 weeks of age52. Specifically,
these mice exhibit a characteristic crescent-shaped region of fibrosis in the epicardium of
the left ventricle, which is also observed in the human condition53; this abnormal fibrosis
is not localized and affects all regions of the ventricle similarly49. The mice also exhibit a
short stature, abnormal gait, severe kyphosis, joint contracture, hind limb weakness,
labored breathing, abnormal electrocardiogram (ECG) patterns, tachycardia, and
premature death before 20 weeks of age54. Recent evidence revealed that mdx:utrn-/- mice
show dysregulation in matrix metalloproteinases (MMPs) which in turn leads to cardiac
involvement53. Other degenerative changes in bone and cartilage make them an effective
phenocopy of the human condition, which is evident in Figure 1.2.
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Figure 1.2 DMD mouse models. Representative image showing both a) the mdx
dystrophin-knockout mouse model of DMD, and b) the mdx:utrn-/- dystrophin/utrophin
double-knockout model. Note the abnormal stature, kyphosis, posture, and muscle
contraction in the double-knockout mouse compared to the mdx mouse, which appears
relatively unaffected. Photo courtesy of Kelly Gutpell.
Thus, the mdx:utrn-/- mouse proves to be more representative of true DMD than the
ubiquitous mdx model for pre-clinical investigation of DMD-related cardiomyopathy and
novel therapies. Importantly, no other single- or double-knockout mouse shows
significant changes in cardiac involvement or fibrosis in the same manner as mdx:utrn-/mice30. Longitudinal assessment of cardiac function in this strain is thus crucial to
quantitatively determine the progression of cardiomyopathy, which would further our
fundamental understanding of murine dystrophy, and would also be essential in
optimizing in vivo therapies. Recent research employing non-invasive, longitudinal
techniques in the mildly-affected mdx mouse has elucidated valuable information about
its cardiac function49,54–59. Nevertheless, the double-knockout model has not received the
same degree of research interest, and most of the current knowledge of its cardiac
manifestations are based on terminal techniques. For instance, early functional studies in
the mdx:utrn-/- mouse determined contractile dysfunction in the heart via cardiac muscle
preparation52. However, this study was performed using muscle fibres from the right
ventricle, and in order to obtain these, mice had to be euthanized, eliminating the
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possibility of longitudinal cardiomyopathy progression studies. Few groups have focused
on characterizing cardiomyopathy in the dystrophin- and utrophin-deficient mdx:utrn-/mouse non-invasively. Two studies employed cardiac MRI16,59, which is an expensive
and time-consuming procedure. Another study employed ultrasound, namely motionmode (M-mode) echocardiography38. While it is a cost-effective alternative, M-mode is
inherently very prone to inaccurate measurements (discussed in detail below). This
emphasizes the need for an alternative method of non-invasively assessing the extent and
progression of cardiomyopathy in the mdx:utrn-/- mouse that is cheap, quick, and
relatively easy to perform, which would be a great asset for therapeutic studies.

1.4

Treatment Strategies for DMD

To date, no cure for DMD exists, and even with clinical intervention, the disease remains
invariably fatal before 30 years of age60. Historically, treatments have been largely
palliative, which has indeed afforded patients longer life expectancy and quality of life32.
In the past twenty years, advances in walking and ventilation support have eased the
maintenance of the disease even more. In terms of therapy, the current clinical standard is
a glucocorticoid called prednisolone, which slows the progression of the disease by
reducing the inflammatory response31,61. However, responses to this therapy have been
mixed—improvements in muscle strength and function are generally seen, but they are
short-term, lasting from six months to two years. Many adverse effects have also been
observed as a direct result of this therapy, and no true long-term data on glucocorticoid
treatment exists to validate its efficacy62. Furthermore, steroid therapy poses a very
serious risk of osteoporosis when used over a long period of time31. Given the osseous
involvement in DMD, such a therapy is not feasible.
In recent years, novel and innovative approaches have been investigated to tackle DMD;
these can be divided into four overarching categories: gene replacement therapy, utrophin
up-regulation, exon skipping, and cell therapy1. The first involves the delivery of a
truncated-but-functional dystrophin gene, termed a ‘micro-dystrophin’, through an
adenoviral vector to the patient. The viral vector was used as it delivers the genetic
material to cells ubiquitously through transduction. Indeed, studies using microdystrophin have shown excellent results in animal studies63, which led to a clinical trial.
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However, it showed limited success—the therapy did not restore adequate dystrophin
expression and was plagued by host rejection, wherein an immune response was
produced against myocytes that novelly expressed the protein64. Moreover, gene therapy
has shown little beneficiary effects on the heart in animal studies65.
Utrophin up-regulation, as its name implies, involves using high levels of the analog
protein in humans. In adults, utrophin is 80% homologous to dystrophin and is primarily
found at neuromuscular junctions, with little found along the sarcolemma postpartum16,66,67. Nevertheless, it has the ability to localize there and confer function,
particularly after exercise68. Experiments using mdx mice have shown that up-regulation
of utrophin can reduce blood creatine kinase levels by 25%9. Treatment strategies in adult
tissue work at multiple levels, with drugs administered to up-regulate expression of the
utrophin gene, while others up-regulate chaperone proteins to bring utrophin to the
sarcolemma. Unfortunately, none of these approaches have resulted in high enough upregulation, and mdx mice retained the DMD phenotype after treatment1.
Exon skipping is a technique by which a faulty region of a gene is ‘skipped’ when
generating protein. It uses small pieces of RNA called antisense oligonucleotides (AONs)
that either block splice sequences or alter host mRNA folding69,70. DMD involves a stop
mutation, and thus skipping the faulty stop codon renders a mostly functional protein that
ameliorates symptoms, giving rise to a more BMD-like phenotype71. Indeed, several
clinical trials have taken place using exon skipping. Nevertheless, these showed poor
uptake of AONs into cells, fast clearance from the bloodstream, and variable efficiency
depending on the specific dystrophin mutation—the treatments were all targeted to exon
51. Importantly, the clinical trials showed little efficacy in the heart; if exon skipping
therapy were to become widely-adopted, it would cause cardiomyopathy to become much
more prevalent in patients treated with AONs1,50,59. Moreover, the resulting increase in
skeletal muscle function in these patients may cause them to be more active, putting a
greater strain on their weak heart59; the same problem also applies for micro-dystrophin
gene therapy.
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1.4.1

Stem Cell Therapy

The key to slowing or attenuating DMD-associated cardiomyopathy may be an approach
that promotes the regeneration of injured tissue. In this respect, a good candidate is
exogenous stem cell therapy. When administered to injured tissues, stem cells have been
reported to improve cardiac function through multiple mechanisms, including direct
replacement of cardiomyocytes through cellular differentiation of implanted cells72,
fusion with endogenous cardiac cells73, and also through paracrine effects, i.e. stimulating
the endogenous host cells to regenerate injured tissue50,74. The replacement of old,
diseased tissue with new, healthy, and fully functional one may confer a much more
substantial benefit to patients and could improve clinical outcome on a long-term basis.
Stem cells are categorized into two major subtypes: embryonic stem cells (ESCs), or cells
derived from the inner mass of the blastocyst, and adult stem cells, which are resident in
developed organs and function to replenish tissues throughout postnatal, childhood, and
adult life. The former have received great scientific attention in recent years as they
readily self-renew to generate large numbers of cells for regenerative purposes75; their
characteristic pluripotency allows them to differentiate and regenerate many tissues of the
body76. Indeed, ESCs have been shown to be effective at regenerating myocardium77, and
evidence has shown that these cells are capable of restoring dystrophin75. However, they
suffer from a large and significant caveat—ethical concerns over obtaining cells from
human embryos drastically hinder their future translational applicability. An ingenious
solution to this problem is to use induced pluripotent stem cells (iPSCs), or adult cells
that are reverted into a pluripotent, ESC-like state. While these cells may circumvent the
aforementioned ethical issues, the field of iPSC therapy is still in its infancy, and much
research is needed to optimize their mechanism of reversion before extensive
regeneration experiments can be performed78,79.
Adult stem cells have also received a great deal of research interest, and are now being
very actively investigated for CVD treatment80. The earliest studies used bone marrowderived stem cells, which were shown to be capable of alleviating the effects of
myocardial infarct, or heart attack81. However, further investigation into this stem cell
type showed that they ultimately demonstrate poor long-term engraftment potential,
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while not being reflective of true myocardial regeneration82. Another type of stem cell
that has been investigated is the skeletal myoblast. While these cells showed excellent
potential for treating DMD in initial mdx mouse studies83, a subsequent clinical trial in
skeletal muscle revealed a very poor regenerative capacity, with novel myogenesis in
only 1 of 12 patients84. Importantly, skeletal myoblast therapy was investigated in the
heart, and while the transplanted cells indeed engrafted into the host tissue, they also
produced dangerous arrhythmias82. This may have come as a result of these types of
cells’ inability to form functional and active electromechanical coupling with the host
tissue85,86. Mesenchymal stem cells have also been explored, as they have been shown to
be able to differentiate into mesodermal cells, couple with host tissue, and elicit paracrine
stimuli to endogenous cells1,87. Studies with mesenchymal stem cells in rats showed they
are able to differentiate into cardiac muscle and can confer some improvement in
function in non-ischemic cardiomyopathy88. They have also been used in DMD
therapeutic research, but unfortunately did not produce an adequate degree of contractile
improvement89, which is crucial to treating such a condition.
Thus, none of the aforementioned cell types have been determined to be an optimal
candidate for DMD cardiac therapy. Importantly, none of these cells constitute true
myocardial regeneration82. Due to the limitations of these cell types and the ethical
concerns over ESCs, an approach using cardiac-specific autologous or histocompatible
stem cells may be the best option for treating heart disease and DMD cardiomyopathy.

1.4.2

Cardiac Stem Cells (CSCs)

Until roughly the last decade, the general consensus among scientists was that the heart
was a terminally-developed organ without the capability for self-renewal or
regeneration90. However, research has uncovered a new population of multipotent
stem/progenitor cells resident in the adult heart; these are known as cardiac stem cells
(CSCs). CSCs were first discovered in rats by Beltrami et al.91; they isolated a population
of cells that were able to self-renew, and were found to have the potential to differentiate
into all three cell types present in the heart—cardiomyocytes, endothelial cells, and
smooth muscle cells. Human CSCs are characterized by their expression of tyrosine
protein kinase kit (c-Kit), the receptor for a cytokine known as stem cell factor/kit ligand.
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They also lack expression of common hematopoietic lineage surface markers such as
CD34 and CD45, and have also recently been found to express stage-specific embryonic
antigen 4 (SSEA-4), a well-known marker of stemness and pluripotency in ESCs92.
Importantly, CSCs are well-documented to have a high capacity for cardiomyocyte
regeneration93, and preferentially differentiate along a cardiomyocyte lineage as
evidenced by high levels of cardiac transcription factors such as Nkx2.5, myocyte
enhancer factor 2C (MEF2C), and GATA494. Studies indicate that, on average, about
50% of adult cardiomyocytes are replaced during a healthy human life span90,95, while in
mice, novel cardiomyocyte formation occurs in the adult heart following injury96; these
are thought to arise as a result of CSCs.
Thus, these stem cells may be an excellent candidate for therapy due to their being
enriched for stem/progenitor cell activity, and their ability to successfully differentiate
into cardiomyocytes in vitro87. Since their initial discovery, multiple subsets of CSCs
have been identified in both the human and mouse heart, including c-Kit+ cells, side
population (SP) cells, cardiosphere-derived cells, and stem cell antigen 1-expressing
(Sca-1+) cells. The first, c-Kit+ cells, are arguably the most relevant CSC population in
humans; they can be cultured for extended periods of time to generate clinically relevant
numbers, which have been shown to have up-regulated expression of cardiac
transcription factors such as GATA47. Indeed, these cells have shown a striking ability to
regenerate functional cardiomyocytes and prevent remodeling in diseased hearts, while
also conferring functional improvement; this led to their inclusion in the SCIPIO clinical
trial, which showed promising initial results97. Nevertheless, they are a rare population of
cells in the mouse98, and very recent contending evidence has shown they largely
generate endothelial tissue in mice99. Cardiac SP cells, notably characterized by their
exclusion of Hoechst 33345 dye, have been described as much more heterogeneous,
expressing any number of surface markers, including CD31, CD34, CD45, c-Kit, and
Sca-1100. SP cells were shown to be tissue-specific and cardiogenic, expressing high
levels of both Nkx-2.5 and cardiac troponin T (cTnT). However, they are a curiously rare
population in the murine heart, and to date, their therapeutic potential remains in
question7. Moreover, the expression of hematopoietic and bone marrow-specific cell
markers may lead to certain limitations; for example, CD34+ cells have been shown to
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preferentially differentiate into endothelial cells and hematopoietic cells101, while CD31+
cells do not show cardiomyogenic potential in the same manner as CD31- cells do102.
More recently, cardiosphere-derived cells, which are directly grown from human biopsy
specimens, have been investigated. Cardiospheres were first described by Messina et
al.86, who showed that a population of cells obtained from explant culture readily formed
multicellular clusters, or spheres, in culture. Cells derived from these cardiospheres have
been shown to engraft, differentiate, and secrete angiogenic/anti-fibrotic cytokines in the
injured heart that ultimately conferred functional benefit103; indeed, successful preclinical results led to these cells’ use in the CADUCEUS clinical trial, which presented
promising improvements in cardiac wall thickening and contractility. However, further
research needs to evaluate these cells over the long term, as they did not show significant
improvements in left ventricular ejection fraction (EF), the gold-standard measurement of
cardiac systolic function. Moreover, mixed populations of cardiosphere-derived cells
express CD31 and CD34, and some reports have contested their efficacy as being due to
retained cardiomyocytes and their stemness as falsely attributed to hematological
contamination104.
When discussing pre-clinical stem cell research, specifically as it relates to DMD, certain
aspects must be considered. While the above cell types are relevant CSC populations in
humans, they have been shown to be relatively rare in the adult murine heart7,98,105, and
thus, would not be ideal cell populations to use for investigating regenerative therapies.
In humans, these cells must be cultured and expanded in order to get clinically relevant
numbers. Even after expansion, one may not be able to obtain enough cells to elicit a
regenerative effect. Thus, they are not an ideal choice for time-sensitive applications in
the severely dystrophic mdx:utrn-/- mouse. Furthermore, it remains unclear whether these
subtypes are distinct, or are different developmental manifestations of a single CSC
type106. In these respects, the Sca-1+ subtype of CSCs may be key. These murine cells,
which also lack expression of c-Kit and hematopoietic markers107,108, have been found to
be capable of self-renewal and clonogenesis, while also being largely dedicated to the
cardiomyocyte lineage105,109–111. Specifically, some groups have shown that Sca-1+ cells
can generate beating cardiomyocytes in culture with 80-90% efficiency112. Sca-1expressing cells were able to partially restore function after transplant to injured hearts,
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and have been shown to up-regulate paracrine effectors inducing angiogenesis, while also
supporting the expansion of other CSCs in the injured heart106,108. Sca-1 knockout mice
exhibited severe cardiomyopathy, stressing its importance to cardiac development113,114.
Although a definitive human equivalent to the murine Sca-1+ cell has not yet been
discovered, several functional orthologs exist, and Sca-1 has been used as an alternative
marker to identify stem cells7,113. Research using the Sca-1+ population may uncover the
subtle details that characterize them as a distinct subtype of CSC, and may also help
investigate CSC delineation and the conditions needed for regenerative CSC therapies.
As such, results from this research may have translational value when investigating CSC
therapies in humans.
Importantly, a stem cell therapeutic approach using CSCs may aid in DMD tissue repair
not only by regenerating damaged muscle tissue, but also indirectly, by combatting the
three major hindrances to endogenous repair: ischemia, inflammation, and fibrosis40.
Autologous CSCs are known to stimulate stem cells in the host, including endogenous
CSCs and endothelial progenitor cells115, and may further produce angiogenesis and
neovascularization through paracrine secretion of vascular endothelial growth factor
(VEGF)116. In this way, CSCs may be able to ameliorate the defective secretion of proangiogenic growth factors that has been evidenced in pre-clinical models of DMD-related
cardiomyopathy41,115. They have been shown to reduce inflammation and modulate the
immune response to suppress the fibrotic scars evident in diseases such as DMD, which
may promote an adaptive healing process115. Furthermore, by regenerating functional
myocardium, CSCs may also prevent the recruitment of fibroblasts, further ameliorating
fibrosis.

1.5

Non-Invasive Pre-Clinical Imaging

The necessity of reliable, non-invasive methods of assessing disease quickly becomes
clear when trying to develop methods to assess both degenerative changes over time in
DMD, and also the efficacy of therapeutic applications. Medical and molecular imaging
techniques targeting biomarkers and reporter proteins have become complementary to in
vitro and ex vivo methods in studying cardiomyopathy and cell therapy. The advent of
new imaging technologies has allowed unprecedented amounts of information to be
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obtained in great detail without the need for invasive procedures, in both mice and
humans. A number of imaging techniques, such as ultrasound, have been applied to study
DMD-related cardiomyopathy in the clinic36, and imaging may be an indispensable tool
when studying the disease at the pre-clinical level.

1.5.1

Ultrasound

Ultrasound is an imaging method that uses high-frequency acoustic waves that are
beyond the range of human hearing to examine tissues within the body. The ultrasound
probe, or transducer, emits pulsed ultrasonic waves through a conducting gel into the
body. These sounds are reflected wherever changes in density and compressibility exist,
which correspond to changes in acoustic impedance; this occurs between tissue
boundaries, and produces ‘echoes’ which are then picked up by the transducer. The
signals are processed by the scanner, which generates images based on the strength of the
echoes and time it takes them to return to the transducer. There is a trade-off between
imaging depth and resolution, depending on the frequency of the emitted sound—lowerfrequency ultrasonic waves produce deep tissue penetration with low resolution, whereas
higher-frequency ultrasound produces very detailed images, albeit with low tissue depth.
Ultrasound has been very popular in the clinic due to its low cost, portability, and ability
to produce images in real-time; as such, it has found clinical application in such fields as
cardiology, obstetrics, and surgical guidance. It can also take advantage of the Doppler
Effect to provide blood flow analysis, important in the imaging of heart valve
dysfunction.
Over the last decade, this method has found widespread popularity in studying heart
disease in small animals. Technological advances in the manufacture of piezoelectric
crystals and multi-element ultrasound transducers has permitted the use of high resolution
ultrasound to generate images of striking quality in rodents117. This technology enables
systolic function to be measured non-invasively in mice using small animal scanners,
which produce images at a frequency range of 20-60MHz. Transthoracic microechocardiography, or the imaging of the heart via ultrasound, offers a powerful noninvasive alternative to gauge morphometry and function in the living animal118. As
opposed to other tomographic imaging methods, echocardiography is quick, cheap, high
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resolution (as fine as 30µm)117, can provide real-time data, and is more accessible than
other methods. However, it is operator-dependent, with a high chance of intersonographer variability. Furthermore, artifacts in the image are introduced by hair and
ribs, which may block certain regions of the heart depending on the orientation of the
transducer and the transmitted frequency. Despite these shortcomings, the absence of
injectable contrast agent, as well as cost- and time-effectiveness, make echocardiography
ideal for the assessment of cardiac function in frail mouse models of disease, which may
not handle contrast agents like their wild-type (WT) counterparts.

1.5.1.1

Limitations of 2D Echocardiography

A common method of determining cardiac systolic function and cardiomyopathy is by
measuring cardiac output. This can be described by stroke volume (SV), or the volume of
blood pumped by the heart with each heartbeat, obtained by subtracting end systolic
volume (ESV) from end diastolic volume (EDV) for the left ventricle. It can also be
described by ejection fraction (EF), which is equal to SV/EDV, and represents the
fraction of blood pumped out of the ventricle with each heartbeat3,119. Until recently, the
use of ultrasonic methods was hampered by the small size and fast heart rate (around
400-700bpm) of mice120, and few systems were able to produce information of enough
quality to develop quantitative results121. For this reason, and likely due to its relative
simplicity, the most popular means of determining SV and EF has been through onedimensional motion-mode echocardiography (M-mode)120,122–124. This involves placing
the ultrasonic transducer over the left parasternal line and obtaining either a long or short
axis view through the centre of the heart121; an M-mode image with high temporal
resolution is obtained, from which the one-dimensional value for left ventricular internal
diameter (LVID) at both diastole and systole (LVIDd and LVIDs, respectively) is
determined by measuring the distance from the anterior to posterior facets of the
endocardium. Subsequently, a correction formula known as the Teichholz’ formula (Vol
= 7/(2.4 + LVID) + LVID3) is applied to these linear measurements in order to estimate
the values for EDV and ESV125,126. Another measurement, known as fractional shortening
(FS), is calculated from LVIDd and LVIDs through the formula FS = (LVIDd – LVIDs) /
LVIDd37,127,128. FS is preferred by some as an alternative to EF, as a greater cavity
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obliteration in mice produces a much larger EF value than seen in humans126. The Mmode method is relatively quick and provides rapid EF and FS calculations by applying
the assumption of an overall geometric model to the heart125.
However, M-mode is prone to inter- and intra-user variability129, and may be inaccurate
due to the inherent assumptions made in order to convert a linear value into a threedimensional volume130,131. Indeed, reports of inter- and intra-user variability and bias
with this methodology are well noted—patient studies show that the Teichholz method
produced the widest limits of agreement compared to CT132, with EDV values showing
the weakest correlation, often resulting in a significantly over- or under-estimated
EF129,133. Furthermore, the assumption of shape inherent in the Teichholz method may
cause even greater discrepancies when studying diseased hearts such as those affected by
dilated cardiomyopathy, as these specimens may not have the same geometry as healthy
hearts128,131,134. The presence of regional wall motion abnormalities such as those present
in heavily fibrotic hearts may call for an entirely different approach altogether126,128.
Indeed, the practice of using the Teichholz’ formula to measure EF in the clinic has been
discouraged for some time130, but in pre-clinical models, it arguably remains the most
widely-used method of assessing systolic function.

1.5.1.2

Three-Dimensional Echocardiography (3DE)

With the advent of very high-frequency ultrasound scanners, three-dimensional
echocardiography (3DE) has become possible in mice with the help of dedicated 3D
motors and physiological monitoring—the motor functions to sweep the transducer in the
z-plane to produce slices, while physiological monitoring permits prospective ECG and
respiratory acquisition gating, allowing sonographers to generate stitched 3D volumes of
the heart at systole and diastole135,136. Although gated 3DE requires more scan time
(around 30 minutes total time per scan), it proves to be more accurate than M-mode, and
is much cheaper and quicker than the standard MRI method for 3D measurement of
cardiac function, while producing similar results137. Nevertheless, 3DE produces gating
artifacts which are apparent in views perpendicular to the sweep axis136.
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1.5.1.3

Echocardiographic Evaluation of DMD Mouse Models

Although cardiomyopathy in mdx mice has been described longitudinally in great detail
through non-invasive imaging49,54–59, mdx:utrn-/- mice have not received as much research
interest16,59. The mdx:utrn-/- dystrophic mouse is one of very few small animal models
available to date with which to study the dilated, non-ischemic form of
cardiomyopathy—the others being hamsters44. Thus, quantitative evaluation of cardiac
ventricular sizes, ventricular function, and left ventricular mass, first in mdx:utrn-/dystrophic mice, is important for prognosis and management of the disease in patients.
To this end, Chun et al.38 have recently characterized DMD-related cardiomyopathy in
mdx:utrn-/- mice using M-mode echocardiography. In this study, the authors found that by
15 weeks of age, dystrophin/utrophin-deficient mice exhibit a decrease in left ventricular
EF and FS, and an increase in EDV, left ventricle dilation, and thinning of the ventricular
wall and septum, relative to healthy WT mice. Nevertheless, a limitation of this study is
the M-mode procedure used to measure changes in cardiac output/ventricular function.
Aside from the aforementioned errors arising from geometrical volume assumptions, the
M-mode method may not be sensitive enough to detect early changes in cardiomyopathy.
As such, the subtle effects that may come as a result of therapies can go unnoticed. No
studies to date have investigated the progressive changes in cardiac function caused by
DMD-related cardiomyopathy in mdx:utrn-/- mice using 3DE.

1.5.2

Micro-CT

X-ray computed tomography (CT) also plays a steadily increasing role in the field of
cardiac imaging. This imaging technique uses high-energy electromagnetic radiation to
produce images of the internal organs of the body. Briefly, x-rays are emitted from an
energized source on a moving gantry that rotates 360° in a single axis around the patient.
A detector located opposite the source measures the attenuation of the emitted x-rays by
tissues at multiple points along the 360° rotation of the gantry, providing this information
to a computer. Through an algorithmic process known as filtered back projection, the
computer reconstructs cross-sectional tomographic images through the body of a patient,
which are isotropic and can be rendered in three dimensions for interpretation.

24

Image contrast is dependent on the degree of x-ray attenuation by different matter in
tissues, measured in Hounsfield units. Since the soft tissues of the body are largely
composed of water, their inner details are generally not discernable on CT images. For
this reason, contrast agents based on iodine and barium are administered through various
routes in order to improve the interpretability of the images, and also to provide
functional and dynamic information (e.g. blood flow and perfusion). This allows CT to
provide insight into the body, which is a great asset in the clinic. Despite the delivery of a
discernible dose of ionizing radiation, CT is widely used in studying bones, lungs,
abdominal conditions, cancer, and CVD.
In vivo cardiac micro-computed tomography (micro-CT) technology has also recently
evolved to permit quantitative measurement of cardiac structure, function, volume, and
mass in small animal models of heart disease; it has proven to be very reliable and
accurate, while also being faster and cheaper than other tomographic methods such as
MRI138. Potential advantages of micro-CT over traditional methods, such as M-mode
echocardiography, include 3D volumetric assessment of cardiac chambers without the
need for geometric assumptions139–141. This method employs a vascular, iodinated
contrast agent in order to differentiate the myocardium from the blood pool. ECG and
respiration are monitored, and using these parameters, retrospective gating can be
employed to produce images at systole and diastole, respectively. Micro-CT produces
high-resolution images that provide an incredible amount of anatomical and structural
detail; as such, it is generally considered to be one of the gold standard tomographic
techniques for assessing systolic function142. The injection of contrast agent may
inadvertently have negative impacts on severely diseased mouse models. Despite this
shortcoming, it is highly appealing as a reference point for other imaging technologies,
such as 3DE.

1.5.3

Non-Invasive, Echocardiography-Guided Delivery of
Therapeutics

One of the most important aspects of a therapy is its method of delivery. A number of
groups investigating cardiac therapies have approached the problem by delivering the
therapeutic agent systemically via intravenous (IV) administration7. However this may be
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disadvantageous, as the therapeutic agent is not being directed wholly to the affected site,
resulting in nonspecific delivery; as such, large quantities of an agent may be necessary
to see any effect143. For this reason, groups have begun to use direct intra-myocardial
(IMC) injections to deliver treatment directly to the injured heart43. Unfortunately, the
small size of the murine heart hinders the accuracy of the injection into the affected site
in the left ventricular wall. To ensure optimal injections, labs have very often employed
highly-invasive thoracotomy procedures which require a skilled surgeon, and even in the
best cases, may lead to long-term complications in the mouse. These types of procedures
are also not ideal for repeated injections and time-sensitive experiments.
A technique that is quickly gaining ground involves delivering therapeutic agents directly
to the affected site under ultrasound guidance. Recently, several reports have surfaced
exploring the feasibility and accuracy of closed-chest thoracic injections into mice using
ultrasound-guided needles43,143–147. These describe success in the delivery of a bolus
within the left ventricle, into the myocardium, and into the pericardial space under
ultrasound guidance. Springer et al.43 were the first group documented to perform an IMC
injection under ultrasound guidance. They tested the method against a typical open-chest
procedure, and further used it to deliver both a fluorescent tracer and skeletal myoblasts
into an infarct model. Despite their pioneering success with this technique, no therapeutic
assessment was carried out in this study. Nevertheless, later research from this group
showed improvements in heart function in mouse models of myocardial infarct; these
came as a result of IMC injection of extracts from bone marrow and mononuclear
cells144–146, as well as from the implant of human ESC-derived cardiomyocytes. Thus far,
they are the only group to actively perform IMC injections under ultrasound guidance for
therapeutic research. Laakmann et al.143 showed success injecting a viral vector into the
pericardial space under ultrasound guidance, targeted towards the right atrium; however,
this was largely performed in wild-type mice. Moreover, despite not being a therapeutic
study, Zhou and Zhao147 recently published a methodological article outlining ultrasoundguided injection of breast cancer cells into the left ventricle. This method of producing
breast cancer brain metastases has been adopted by other groups as well148. Evidently, all
of these procedures varied in terms of delivered agent and route of administration, and
the therapeutic studies have been largely focussed on mouse models of myocardial
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infarct. Thus, the methodology remains to be explored in a model of dilated
cardiomyopathy.
Despite their differences, these groups have established that IMC implant is an accurate
and valid delivery method that is more effective than traditional systemic alternatives. It
is fast, circumvents the need for highly trained veterinary surgeons, and avoids the
stringent requirements and complications of thoracotomies, while maintaining the ability
to deliver both drugs and biological agents in a targeted manner. This method is
especially appealing when considering dystrophic mdx:utrn-/- mice, where surgery would
be further complicated by their severe kyphosis and bone abnormalities. Importantly, a
thoracotomy would greatly aggravate the already-present inflammation and fibrosis
present in these mice. Thus, the implementation of a closed-chest, ultrasound-guided
IMC injection method has great merit.

1.6

Rationale, Objectives, and Hypotheses

While new and promising experimental strategies are being developed to ameliorate the
skeletal muscle manifestations of DMD, few have been shown to have any efficacy in the
myocardium. This stresses the need to develop a novel, effective CSC therapy for DMDrelated cardiomyopathy. Furthermore, such a therapy needs to be investigated first in an
appropriate pre-clinical model of DMD, with well-characterized and effectively delivered
cells, while also requiring an accurate and sensitive method to gauge small changes in
cardiac function longitudinally. The objectives of this dissertation are as follows:
1) To implement a three-dimensional echocardiography (3DE) technique to measure
systolic function in mdx:utrn-/- mice, validate its accuracy against current gold
standard micro-CT, compare its inter-/intra-user variability against traditional M-mode
echocardiography, and use it to determine the progression of dilated cardiomyopathy
in the mouse model.
2) To isolate and characterize a subtype of Sca-1+ cardiac stem cells (CSCs) from the
hearts of healthy mice as a potential avenue for regenerative therapy, and determine
their ability to differentiate into a cardiac lineage in vitro.
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3) To explore the accuracy and feasibility of a minimally-invasive, closed-chest,
ultrasound-guided injection technique to deliver therapeutic agents directly to the left
ventricular myocardium in vivo.
4) Given the previous objectives, to combine these techniques to determine any
regenerative effects that freshly-sorted Sca1+ CSCs may have on mdx:utrn-/- systolic
function.
It was hypothesized that the use of 3DE would correlate well with micro-CT analyses of
cardiac volume, and importantly, would provide greater accuracy with less bias and
variability than standard M-mode. Furthermore, 3DE was expected to be a feasible and
useful tool for determining cardiomyopathy in mdx:utrn-/- mice, in which a decrease in
cardiac systolic function was hypothesized to occur in dystrophic animals as compared to
healthy controls. Sca-1+ CSCs isolated from healthy mice were expected to grow readily
in culture, and after differentiation, express markers of adult cardiac tissue. The proposed
method of implanting these cells under ultrasound guidance was speculated to cause very
little harm to the animal, and post-mortem evaluation was expected to confirm its
accuracy and targeting ability. Lastly, transplanted CSCs were hypothesized to have a
beneficial effect on mdx:utrn-/- cardiomyopathy at 5-10 weeks post-implant, manifested
as a reduced deterioration of functional parameters compared to untreated mice.
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2

Materials and Methods

For the sake of clarity and brevity, the methodology used for each objective is outlined
first, followed by a detailed description of the methods used herein.
Objective 1i: To validate three-dimensional echocardiography (3DE) and use it to assess
cardiac function, power analysis was first conducted. mdx:utrn-/- (n = 5) and wild-type
(WT; n = 8) mice were then imaged via motion-mode echocardiography (M-mode), 3DE,
and micro-computed tomography (micro-CT) at 6-8 weeks and 15-17 weeks. The
accuracy of each echocardiographic method was determined by comparing its
measurements to micro-CT via Bland-Altman analysis. Variability within measurements
obtained with either echocardiographic modality was determined via intra-class
correlation analysis. Next, differences in the progression of cardiomyopathy between and
within groups was assessed from 3DE measurements via two-way mixed-design
multivariate analysis of variance (ANOVA) with Tukey’s post-hoc test. Findings were
confirmed histologically via Masson’s trichrome and hematoxylin/eosin staining; a twoway ANOVA with Tukey’s post-hoc test was used to compare measurements (all groups
n = 3 for histology).
Objective 2: In order to isolate and characterize a novel population of Sca-1+ cardiac
stem cells (CSCs) as a potential therapeutic agent, 6-12-week-old wild-type mice were
used. Cells from their hearts were obtained via fluorescence-activated cell sorting
(FACS). They were propagated in culture, differentiated, and their cardiomyogenic
potential was assessed via fluorescence immunocytochemistry.
Objective 3: To determine the accuracy and feasibility of an ultrasound-guided injection
technique to deliver therapeutic agents directly to the myocardium, various test
experiments were carried out. The accuracy of the injection was examined in WT mice (n

i

Work related to this objective was adapted from the published article Bondoc BA, Detombe S, Dunmore-Buyze J,
Gutpell KM, Liu L, Kaszuba A, Han S, McGirr R, Hadway J, Drangova M, and Hoffman LM. 2014. Application of
three-dimensional echocardiography and gated micro-CT to assess cardiomyopathy in a mouse model of Duchenne
muscular dystrophy. Ultrasound Med Biol 40(12): 2857-2867. Copyright, with permission from Elsevier (Appendix A).

29

= 3) in real-time using a microbubble contrast agent; furthermore, the targeting ability of
the technique was subsequently confirmed after excision of the hearts through the use of
a blue dye in the bolus. The safeness of the procedure was confirmed by monitoring
saline-injected WT mice (n = 3) over 2 weeks.
Objective 4: Lastly, to determine what therapeutic effects they may have in vivo, CSCs
were isolated via FACS and implanted under ultrasound guidance into mdx:utrn-/- mice (n
= 2). Cardiomyopathy was assessed before implant and 5 weeks post-implant via 3DE,
and trends in the data were analyzed by comparing the implanted mice to the untreated
mdx:utrn-/- mice used in Objective 1.

2.1

Mice and Anaesthesia

All animal protocols were approved by the Institutional Animal Use Subcommittee,
(Western University, London, ON, Canada) and conducted according to guidelines set by
the Canadian Council on Animal Care (CCAC); ethics approval documentation can be
found in Appendix B. mdx:utrn-/- mice were produced by breeding pairs of mdx mice
heterozygous for the utrophin gene (mdx:utrn+/-; generously supplied by Dr. Robert
Grange, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA; strain
originally created by Drs. Mark Grady and Joshua Sanes, Washington University, St.
Louis, MO, USA149). The offspring were genotyped by PCR; these mice were fed a diet
of soft food and monitored every other day to ensure proper health. Mice that declined in
health, characterized by a loss of 15% body mass, lethargy, dehydration, labored
breathing, and lack of appetite, were euthanized to prevent suffering. As controls and to
obtain healthy Sca-1+ CSCs, wild-type C57BL/6 mice (6-8 weeks of age) were purchased
from Charles River Laboratories (Wilmington, MA, USA). mdx:utrn-/- mice were again
used as recipients to determine the effects of Sca-1+ cell implant, with untreated
mdx:utrn-/- mice used as controls.
For all imaging studies, mice were individually placed in an induction chamber receiving
3% isoflurane in 100% oxygen at a constant flow rate of 1L/min. Once anaesthetized,
mice were removed from the induction chamber and weighed; anesthesia was
subsequently maintained with 1-1.5% isoflurane in 100% oxygen at a flow rate of

30

1L/min. A rectal thermocouple was used to monitor body temperature. Images were only
acquired when heart rate of the mouse was 500 ± 100bpm and temperature was 37 ±
0.5°C, in order to ensure heart function was not affected by the anaesthetic regime150,151.
Anaesthesia and heating were adjusted accordingly to achieve this. In contrast,
throughout the implant process, anaesthesia was maintained with 2% or higher isoflurane
to ensure mice were not sentient during the injection; this was confirmed using the pedal
withdrawal reflex test.

2.2

Echocardiography

All images were acquired using a Vevo 2100 (VisualSonics, Toronto, ON, Canada) highfrequency ultrasound scanner by a method similar to Pistner et al. (2010). Anaesthetized
mice were placed in the supine position on the pre-heated ultrasound stage. Electrode gel
was applied to the paws, which were taped down onto the ECG electrodes of the scanner,
and corneal lubricant was applied to the eyes. Depilatory cream was applied to the chest
region for 1-2min, after which the hair was removed with wet gauze. An MS-400 1838MHz linear array transducer producing 50μm axial by 110μm lateral resolution was
attached to a 3D motor (VisualSonics) that allowed sweeping of the transducer along the
z-axis. Pre-warmed ultrasound gel was placed on the chest of the mouse, after which the
transducer was placed 10°-20° from the longitudinal axis along the coronal plane of the
mouse in order to obtain a long axis view of the left ventricle. Images were acquired at 30
MHz with 27dB gain.

2.2.1

M-mode Imaging

To obtain M-mode images, a long axis view through the centre of the left ventricle was
established just out of view of the papillary muscles using brightness mode (B-mode),
and a line of reference for M-mode was drawn close to the base of the heart; 4.95s cine
images were acquired (Figure 2.1). To simulate user variability, test-retest was performed
by completely lifting the transducer off of the animal, replacing the ultrasound gel, and
rotating the mouse stage in various increments along the transverse and coronal planes.
The transducer was then replaced and images obtained as before; this was repeated to
produce n = 3 for M-mode measurements for each mouse.
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Figure 2.1 Representative M-mode image. a) A brightness mode (B-mode) view of
the heart was attained, after which a line of interest (blue dotted line) was placed through
the centre of the heart. b) Time-lapse cine images were acquired along this line to
generate motion mode (M-mode) images. Ordinate: depth; Abscissa: time (s).

2.2.2

3DE Imaging

For three-dimensional echocardiography (3DE) scans, respiratory and electrocardiogram
(ECG) prospective gating was achieved through the electrodes of the ultrasound system.
Prior to scanning, the respiratory gate was set for end-exhalation, and the ECG trigger
was set at the R-wave for end-diastolic volume (EDV, the volume of the heart when it is
highest at the end of the diastolic phase), and halfway in between two consecutive Rwaves for End-Systolic Volume (ESV, the volume of the heart when it is lowest at the
end of the systolic phase). The ESV gate typically occurred at about 45-65ms after the R
wave, given the heart rate of each animal at the time of scan. Furthermore, the gating
parameters were confirmed at the time of scanning by qualitative evaluation of real-time
gated B-mode images produced by the Vevo 2100 system. Parallel long axis B-mode
slices covering the full volume of the heart were obtained by sweeping the transducer
along the short axis in 50μm steps. Long axis slices were used because they have been
shown to be more accurate than short axis views in this type of acquisition129. 3D maps
were stitched and constructed automatically by the built-in software of the scanner
(Figure 2.2). The transducer was then replaced on the mouse as described previously in
order to obtain n = 3 for both EDV and ESV measurements for each mouse. For
comparison with M-mode measurements, 3DE scans were taken immediately following
M-mode scans.
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Figure 2.2 3D map generated from a 3DE scan. A series of adjacent short axis
250μm-thick slices captured at end-diastole in a 16-week-old wild-type mouse using
three-dimensional echocardiography (3DE). Images are displayed in the superior-inferior
direction from the base of the heart (top left) to the apex (bottom right). The scanner
software constructed the maps from long axis slices acquired under electrocardiogram
and respiration gating; minor breathing artifacts are evident in this view (arrowhead), and
shadows cast by the ribs can also be seen (arrow). Bar = 4mm.
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2.2.3

Echocardiography Image Analysis

All qualitative and quantitative analyses of the images were made using the Vevo 2100
workstation software, version 1.5.0 (VisualSonics). For M-mode cine images, the values
for left ventricular internal diameter at diastole and systole (LVIDd and LVIDs,
respectively) were determined by measuring the distance between the anterior and
posterior endocardium (Figure 2.1b). All myocardial wall thickness and internal diameter
measurements were repeated at least 5 times in different cardiac cycles on the M-mode
image, and the mean for each parameter was obtained. EDV and ESV were subsequently
calculated by using the Teichholz’ formula:
EDV =

7 × LVIDd 3
2.4 + LVIDd

(1)

ESV =

7 × LVIDs 3
2.4 + LVIDs

(2)

Stroke volume (SV), the volume of blood pumped by the heart in one cycle, was
calculated as:

SV = EDV − ESV

(3)

Ejection fraction (EF) was calculated as:
EF =

SV
× 100%
EDV

(4)

With 3DE, the values for EDV and ESV were directly measured from the stitched 3D
images at diastole and systole by manual contouring of the endocardium (Figure 2.3a) in
every fifth parallel long axis slice, giving a 250μm distance between contours. If high
motion artifact was present in a particular slice, an adjacent slice was used. After the
entire endocardium was delineated, the software automatically produced a volume
measurement, and also rendered the volume as an overlay to the data in threedimensional space (Figure 2.3b). The values for SV and EF were calculated as before,
using equations (3) and (4).
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Figure 2.3 Example of 3DE image analysis. a) The left ventricular volume was
determined by manual contouring of the endocardium. Contours were drawn at 250μm
intervals. b) The Vevo 2100 software automatically measured the volume from the
contours, and also generated a three-dimensional rendering of the volume. This served as
an additional confirmation of proper contouring by the sonographer. Bar = 4mm.

2.3

Cardiac Micro-CT

Retrospectively ECG-gated cardiac micro-computed tomography (micro-CT) was
performed using techniques previously described in detail138,152. In brief, eXIA 160XL
(Binitio Biomedical, Ottawa, ON, Canada), a blood-pool contrast agent, was injected
intravenously into anaesthetized mice at a volume of 5µL/g body weight. Clinical
neonatal electrodes were attached to the paws to record ECG, enabling retrospective
gating. Scans were acquired using a slip-ring gantry micro-CT scanner (eXplore Locus
Ultra, GE Healthcare, London, ON, Canada) at 80kVp and 50mA over 10 rotations (5s
per rotation, 416 projections per rotation, total scan time of 50s), with a field of view of
14cm (transaxial) x 5.4cm (longitudinal).

2.3.1

Micro-CT Image Analysis

Cardiac-gated reconstructions were performed by sorting the projection images of each
scan based on the cardiac phase during which they were acquired, thereby allowing for
reconstruction of 3D images at 12ms intervals. In the present study, 9-12 3D images were
reconstructed per cardiac cycle, depending on heart rate. All images were reconstructed
with 150µm isotropic voxels. Images were converted to Hounsfield units prior to
analysis. To calculate left ventricular volume, a threshold level to separate the
myocardium from blood was determined automatically, and done separately for each
scan, as contrast level in the blood changed over the course of the study. A region-
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growing approach was used to automatically segment the left ventricular chamber from
the myocardium. Left ventricular volume was calculated for all the images reconstructed
per cardiac cycle, and the minimum and maximum values for left ventricular volume
were used as ESV and EDV, respectively. EF was calculated using equation (4). Sample
images from each mouse group obtained with each modality can be found in Figure 2.4.

Figure 2.4 Representative images from each mouse group with each imaging
modality. Hearts from a healthy wild-type (WT) mouse and an mdx:utrn-/- mouse are
shown in diastole. a-d) Cine M-mode images representing a full cardiac cycle. e-h) 3DE
long axis slices (50μm thick) with left ventricular contours shown in blue. i-l) micro-CT
coronal slices (150μm thick) from 3D reconstructions. Bars = 4mm.

2.4

Histology

After euthanasia, the chest cavities of the mice were opened and hearts flushed with cold
PBS. Hearts were then extracted and fixed in 10% formalin for 48h, cut into two equally
sized axial sections, and embedded in paraffin. Embedded tissue was sliced in 5μm-thick
serial sections, with representative sections taken at 6 different points along the long axis
of the entire heart. Masson’s trichrome staining was performed in order to gauge the
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progression of fibrosis, and hematoxylin and eosin staining was performed in order to
assess cardiomyocyte hypertrophy153,154. Quantification was conducted by taking five
representative fields of view in each of the four walls of the left ventricle (anterior,
posterior, lateral and septal) using a Zeiss Axioskop microscope (Oberkochen, Germany)
with Northern Eclipse software v7.0 (Empix Imaging, Mississauga, ON, Canada), which
were subsequently analyzed with NIS-Elements BR software v3.1 (Nikon Instruments,
Melville, NY, USA). Fibrosis was assessed by a blinded observer; regions of collagen
content stained in blue were delineated and represented as percentage fibrosis area from
total tissue area. Cardiomyocyte hypertrophy was also assessed by a blinded observer,
where at least 30 cardiomyocytes were delineated in each cardiac wall at each of the 6
points along the long axis, and the average cardiomyocyte area was calculated.

2.5

Fluorescence-Activated Cell Sorting of CSCs

Cardiac stem cells (CSCs) were sourced from 6-12-week-old healthy mice, as previous
studies have shown that CSCs taken from this age group have the most potential for in
vitro proliferation and tissue regeneration155. For each experiment, 4-5 mice were
euthanized and their hearts were excised, followed by manual mincing in a biological
safety cabinet and incubation in a collagenase/dispase solution [1% collagenase B (Roche
Diagnostics, Laval, QC, Canada), 0.25% dispase (Gibco, Carlsbad, CA, USA), and
2.5mM CaCl2 in phosphate-buffered saline (PBS)] for 30min at 37°C in order to generate
a homogeneous suspension of single cells. Following filtration through a 100μm filter
and centrifugation at 530×g for 5min, cells were re-suspended in fluorescence-activated
cell sorting (FACS) buffer [5% fetal bovine serum (FBS; Gibco) in PBS] for staining
with fluorescent antibodies. An aliquot of approximately 5×104 cells was collected as an
unstained control, and multiple aliquots of 5×104 cells were collected for antibody
compensation and fluorescence-minus-one controls. The remaining cell population was
utilized as a source for sorting, using a stringent protocol to isolate Sca-1+ CSCs. 7Aminoactinomycin D (7-AAD; BD Pharmingen, San Diego, CA, USA), a nuclear dye
taken up by non-viable cells, was used to exclude dead cells. The population was further
depleted by using a series of fluorescein isothiocyanate (FITC)-labelled antibodies (BD
Pharmingen) to exclude cells expressing the cell surface markers CD11b, CD31, and
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CD45. These are largely expressed on hematopoietic stem cells and their derivatives156–
158

, and stem cells expressing them show little cardiomyogenic potential102. Cells

expressing CD34, another hematopoietic cell antigen159,160, were also excluded using an
Alexa Fluor 700-conjugated antibody (eBioscience, San Diego, CA, USA). c-Kit was
selected against using a phycoerythrin-cyanine 7 (PE-Cy7)-labelled antibody (BD
Pharmingen). To enrich for the endogenous population of Sca-1+ CSCs, a violet 450
(V450)-labelled antibody against Sca-1 (BD Horizon, San Diego, CA, USA) was used.
Live cells were collected at a rate of up to 3000 cell events/s on a three-laser FACSAria
III cell sorter (BD Bioscience, San Diego, CA, USA) with kind help from Dr. Kristin
Chadwick and the London Regional Flow Cytometry Facility. Forward and side light
scatter were used to differentiate cells from debris based on size.

2.6

CSC Differentiation and Live Cell Microscopy

Immediately following FACS, the isolated Sca-1+ CSC population was pelleted at 530×g
for 5min, re-suspended in growth medium [DMEM/F12 (1:1) + 10% FBS + 100U/mL
Penicillin + 100μg/mL Streptomycin (Gibco)] and seeded onto 0.2% gelatin-coated
Falcon 12-well culture plates (Corning, Tewksbury, MA, USA) at a density of around
1×104 cells/well, depending on FACS yield. The growth medium was replenished every
2-3 days, and the cells were grown to around 90% confluency. At this point, they were
placed in differentiation medium [DMEM/F12 + 2% FBS + 100U/mL Penicillin +
100μg/mL Streptomycin + 1% DMSO]. CSCs were monitored daily and differentiation
medium was replenished every 2-3 days. Cells were differentiated for up to 10 days. Live
CSCs were monitored using an Eclipse TE2000-S inverted fluorescence microscope with
a Digital Sight DS-Qi1Mc digital camera and NIS-Elements BR 3.00 software (Nikon
Instruments). Images were processed using Fiji 2.0.0 (National Institutes of Health,
Bethesda, MD, USA) and Photoshop 7.0 (Adobe Systems, San Jose, CA, USA).

2.7

Fluorescence Immunocytochemistry

To determine their potential to differentiate into cardiomyocytes, Sca-1+ CSCs at days 4
and 10 post-differentiation were fixed in 2% paraformaldehyde for 20min, after which
they were permeabilized with 0.25% Triton-X-100 for 5min. Following a series of
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washes (3×10min) in PBS, slides were incubated in blocking buffer [1% bovine serum
albumin (BSA) and 10% normal donkey serum in PBS] for 1h at room temperature.
Primary antibodies against cardiac troponin T (cTnT, responsible for regulating
contraction; 20μg/mL; Abcam, Cambridge, UK) and Connexin 43 (Cx43, main gap
junction protein in cardiac muscle; 5μg/mL; Sigma-Aldrich, St. Louis, MO, USA), or
against myosin heavy chain alpha (αMHC, part of cardiac myosin contractile complex;
5μg/mL; Santa Cruz Biotechnology, Dallas, TX, USA) and Cx43, were diluted in
blocking buffer and slides were incubated with one of the two solutions overnight at 4°C.
Respective secondary antibodies against mouse conjugated with Alexa Fluor 647, goat
conjugated with Alexa Fluor 594, and rabbit conjugated with Alexa Fluor 488 (all
4μg/mL; Molecular Probes, Carlsbad, CA, USA) were applied for 2h at room
temperature. Slides at day 4 were also stained with Hoechst 33258 (Sigma-Aldrich) for
nucleus visualization. Cover slips were then mounted onto slides using ProLong Gold
anti-fade mountant (Molecular Probes). Cells were visualised with an IX81 motorized
inverted fluorescence microscope (Olympus, Tokyo, Japan) with a CoolSnap HQ2 digital
camera (Photometrics, Tucson, AZ, USA) and InVivo 3.2.2 software (Media Cybernetics,
Rockville, MD, USA). Ten optical sections per region of interest (ROI) were collected in
0.2μm steps along the z-axis using a 60× oil immersion objective lens. The z-stacks were
processed for spherical aberrations and deconvolved using the 3D blind algorithm in
Image-Pro Plus 6.2.1 software (Media Cybernetics). Images were further processed using
Fiji 2.0.0 (National Institutes of Health) and Photoshop 7.0 (Adobe Systems).

2.8

Ultrasound-Guided Injection

The methods described here are roughly based on Springer et al.43. The Vevo 2100
system described herein was used in largely the same manner for cell implants, with
some slight modifications. An injection arm (VisualSonics, catalog number VS-11282)
was mounted on the rail system of the Vevo imaging station. A 10μL Gastight 1801
syringe (Figure 2.5a) with a custom sickle-shaped needle (Figure 2.5b; Hamilton
Company, Reno, NV, USA) was used to draw up the solution to be injected, and was
subsequently mounted onto the injection arm.
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Figure 2.5 Intra-myocardial injection system. a) The 10μL Hamilton syringe used for
ultrasound-guided injections is presented here (1) alongside a traditional 300μL insulin
syringe (2; BD Medical, Franklin Lakes, NJ, USA). Bar = 1cm. b) A transverse
histological section of a mouse heart stained with hematoxylin/eosin is presented along
with the custom sickle-shaped Hamilton needle (3) used in ultrasound-guided injections
and a regular 30 gauge needle (4, BD Medical). Bar = 1mm. c) Overview of the entire
injection system, with major components denoted: 5) mouse; 6,7) stage controls; 8)
transducer control arm; 9) syringe control arm; 10) physiological monitor for
temperature, heart rate, and controlling stage temperature; 11) 3D motor for z-axis
scanning; 12) isoflurane vaporizer; 13) anesthesia induction chamber; 14) heat lamp.
Note the entire injection system is contained within a biological safety cabinet. d) The
mouse (15) was placed in the supine position on the heated ultrasound stage (16); it was
anesthetized with 2% isoflurane (17) and maintained at 36-37°C (18). The ultrasound
transducer (19) was moved slightly inferior from its usual imaging window in order to
visualize the needle (20), which was oriented 20-30° from the stage.
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The sickle-shaped point style was selected as its shape was expected to help contain the
injected bolus within the beating myocardial wall; its parameters were: small RN-style
hub, 30 gauge, 12.7mm length, point style #2. The intended injection target was the midanterior/septal wall of the heart, as it showed the least motion on the sonogram. A substernal, sub-diaphragmatic entry point was established as this route would allow for the
least soft tissue penetration while also avoiding the ribcage. The transducer was oriented
parallel to the needle to be able to visualize its angle and trajectory, and the mouse was
rotated 5-10° clockwise along the sagittal axis to obtain a longitudinal view of the heart.
For the initial penetration of the substernum/diaphragm, the needle was oriented at a 2030° angle from the mouse stage, and the transducer was moved 5-10mm inferior to guide
the needle (Figure 2.5c-d), which was then positioned into the field of view (Figure 2.6a).
This angle was chosen as it was more perpendicular to the mouse and would require less
force on the needle to penetrate the skin. Using real-time image guidance, the needle was
advanced into the thorax of the mouse, and once there, its trajectory was re-oriented
towards the anterior/septal wall (Figure 2.6b). The needle was then carefully advanced
into the myocardium, with some manipulation of the transducer to ensure the needle tip
was within the heart wall. Once this was confirmed, the 10μL bolus was injected very
slowly to prevent leakage into the ventricle or thorax. As a real-time confirmation of
successful implant, the injected volume contained 10% MicroMarker non-targeted
microbubble contrast agent (VisualSonics), which was expected to be visible as a bright,
hyperechoic bolus on the sonogram. The transducer was manipulated by hand during the
injection to ensure there was no leakage; if any was detected, the needle tip was adjusted
accordingly. After injection, the needle was retracted and the mouse was recovered. For
Sca-1+ CSC implants, immediately following FACS, CSCs were pelleted at 530×g and
resuspended in growth medium + 10% MicroMarker at a concentration of 1×104
cells/10μL. The cell suspension was warmed to 37°C to reduce temperature-induced
injury to the recipient mice, and was implanted as described above.
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Figure 2.6 Needle positioning under ultrasound guidance. a) The ultrasound
transducer was adjusted to visualize the needle tip (1), which was placed at a 10-20°
angle from the mouse stage and brought into the ultrasound field of view. For initial
penetration into the thorax, an entry point directly under the sternum (2) was selected,
with the needle’s trajectory (dotted line) aimed posterior to the heart. The needle was
then carefully advanced into the thoracic cavity through the substernum and the
diaphragm. b) The view was adjusted and the trajectory of the needle was then changed
so that it aimed towards its intended target, the mid-lateral/septal wall of the heart (3).
Note the bevel of the needle, visible in a), which was intended to help keep the bolus
within the myocardial wall, and the bright reverberation artifacts present below the
needle. Bar = 4mm.

2.9

Statistical Analysis

To determine optimal sample sizes, power analysis was conducted according to Charan
and Kantharia161. Briefly, an effect size of at least 15% was chosen to be considered
significant for each of the parameters of systolic cardiac function. Given previous work in
mice138, a standard deviation of 12% was used. As such, the minimum number of mice
required to detect this difference, via imaging, at the 95% confidence level with a power
of 0.8 is 5 per group.
Statistical analyses were performed using IBM SPSS Statistics 22 (Armonk, NY) and
plotted using GraphPad Prism 5.03 (San Diego, CA). The accuracies of M-mode and
3DE respectively were determined by Bland-Altman analysis in order to calculate
agreement with and bias against micro-CT; cardiac function measurements in all groups
were pooled and plotted together as percent difference between echocardiography/microCT measurements vs. average echocardiography/micro-CT measurement. To determine
user variability within measurements made by M-mode and 3DE, test-retest was
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performed by taking three scans for each mouse, at each time point, with each method as
described previously in order to simulate different imaging sessions. The data were
analyzed using two-way random-effects intra-class correlation analysis; this was
performed to assess absolute agreement between measurements. Significant (p < 0.05)
intra-class correlation coefficients (ICC) ≥ 0.80 were considered to indicate good
agreement. To evaluate the progression of cardiomyopathy in mdx:utrn-/- mice from 3DE
images, a two-way mixed-design multivariate analysis of variance (ANOVA) with
Tukey’s post-hoc test was used to determine significant differences (p < 0.05) between
measurements in mdx:utrn-/- mice and wild-type controls at baseline (6-8 weeks) and
endpoint (15-17 weeks). For histological analyses, a two-way ANOVA followed by
Tukey’s post-hoc test was conducted to determine significant differences (p < 0.05) in
fibrosis and cardiomyocyte size between baseline and endpoint as well as between wild
type and mdx:utrn-/- mice.
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3

Results
3.1 Assessment of Cardiac Function in mdx:utrn-/- Mice
via 3D Echocardiography

The first goal was to show that a three-dimensional echocardiography (3DE) method was
not only more accurate than the widely-employed motion-mode (M-mode)
echocardiography standard, but also that it was less variable in terms of its
measurements. As a control, gated cardiac micro-CT was used as a gold standard of noninvasive imaging. After its optimization, the ability of 3DE to detect changes in cardiac
function in severely-affected mdx:utrn-/- mice was assessedii.

3.1.1

Accuracy of 3DE and M-mode

One mouse died before its 15-17 week CT scan, and as such, was excluded from this
analysis, resulting in a final sample of n = 24. As illustrated in Figure 3.1, Bland-Altman
analysis revealed that M-mode echocardiographic measurements of end-diastolic volume
(EDV; Figure 3.1a), end-systolic volume (ESV; Figure 3.1c), stroke volume (SV; Figure
3.1e) and ejection fraction (EF; Figure 3.1g) showed considerable bias (overestimation of
EDV, ESV, and SV, underestimation of EF) and wide confidence intervals. In contrast,
far less bias and tighter confidence intervals were found for 3DE measurements of the
same parameters (Figure 3.1b, d, f, h).

ii

Work related to this objective was adapted from the published article Bondoc BA, Detombe S, Dunmore-Buyze J,
Gutpell KM, Liu L, Kaszuba A, Han S, McGirr R, Hadway J, Drangova M, and Hoffman LM. 2014. Application of
three-dimensional echocardiography and gated micro-CT to assess cardiomyopathy in a mouse model of Duchenne
muscular dystrophy. Ultrasound Med Biol 40(12): 2857-2867. Copyright, with permission from Elsevier (Appendix A).
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Figure 3.1 Accuracy of M-mode and 3DE. Bland-Altman plots of functional values
measured via echocardiography vs. micro-CT for each mouse (n = 24). a,c,e,g) M-mode;
b,d,f,h) 3DE. Abscissa: mean of echocardiography and CT measurements; ordinate: %
difference between the two; black line: bias; large dotted lines: 95% confidence intervals;
small dotted line: zero reference. Bias is denoted as % ± SD.
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3.1.2

Variability of 3DE and M-mode

The next goal was to examine the variability present in M-mode and 3DE
echocardiographic measurements, and determine if 3DE measurements showed less bias.
For this purpose, repeated measurements were carried out with either modality as
described above and intra-class correlation analysis was performed to determine absolute
agreement between the three measurements taken within the same mouse. The results of
the analysis are presented in Figure 3.2. Evidently, values obtained through M-mode had
poor agreement (ICC < 0.80), illustrated by large differences of individual scan
measurements from their mean, whereas 3DE values showed very good agreement (ICC
≥ 0.80), with smaller differences of individual measurements from their mean. Note also
that M-mode measurements showed more variability in mdx:utrn-/- mice than in wild-type
mice.
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Figure 3.2 Variability of M-mode and 3DE. Intra-class correlation plots illustrating
variability in measurements obtained via a,c,e,g) M-mode and b,d,f,h) 3DE. Each mouse
(abscissa) was scanned three times; all the values obtained are presented as % difference
between each measurement and the mean within each mouse (ordinate). Dotted line: zero
reference. Significant (p < 0.05) intra-class correlation coefficients (ICC) are noted.
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3.1.3

Evaluation of Ventricular Function in mdx:utrn-/- Mice

After its accuracy and precision were established to be higher than M-mode, 3DE was
used to assess changes in cardiac function in mdx:utrn-/- mice. The findings in the present
study confirm those recently reported by Chun et al.38, namely that mdx:utrn-/- mice
develop dilated cardiomyopathy as early as 15 weeks, as detected by M-mode.
Specifically, in this study, both traditional M-mode and 3DE measurements of EDV,
ESV, SV and EF in healthy C57BL/6 mice relative to mdx:utrn-/- dystrophic mice were
directly compared to those obtained with micro-CT; the pooled mean values for each
group, along with standard deviations, are summarized in Table 3.1. Note that n = 4 for
aged micro-CT mdx:utrn-/- mice as one mouse died before its scheduled 15-17 week CT
scan and was thus excluded from statistical analyses. Of particular interest is the higher
standard deviation of measurements acquired by M-mode echocardiography than by
either 3DE or micro-CT. It is for this reason that further statistical analyses were
conducted on 3DE alone; these results can be found in Figure 3.3.

6-8 Weeks
mdx:utrn-/- (n = 5)

WT (n = 8)
Parameter

M-mode

3DE

micro-CT

M-mode

3DE

EDV (mm3)
ESV (mm3)
SV (mm3)
EF (%)

63.20 ± 15.04
26.68 ± 10.42
36.52 ± 6.15
59.09 ± 7.76

44.12 ± 10.37†
17.95 ± 6.95
26.16 ± 6.14
59.58 ± 8.74

42.40 ± 5.48
15.29 ± 2.80
27.11 ± 5.35
63.63 ± 6.49

51.90 ± 12.78
18.02 ± 7.29
33.88 ± 6.57
67.68 ± 6.67

34.12 ± 9.04
10.62 ± 4.82
23.50 ± 4.49
69.92 ± 6.36

micro-CT
(n = 4)
29.67 ± 2.66
7.97 ± 0.80
21.70 ± 2.44
73.06 ± 2.94

15-17 Weeks
mdx:utrn-/- (n = 5)

WT (n = 8)
Parameter

M-mode

3DE

micro-CT

EDV (mm3)
ESV (mm3)
SV (mm3)
EF (%)

85.83 ± 15.95
43.34 ± 11.34
42.49 ± 7.45
50.33 ± 8.04

63.98 ± 16.67*†
25.35 ± 12.16*
38.63 ± 6.41‡
62.05 ± 8.66

57.32 ± 9.64
18.52 ± 3.86
38.80 ± 6.13
67.84 ± 2.36

M-mode

3DE

74.22 ± 6.76 44.55 ± 8.19*
37.53 ± 13.00 20.23 ± 4.71*
36.69 ± 7.27 24.33 ± 6.67
50.62 ± 14.36 54.03 ± 10.59§

micro-CT
(n = 4)
49.11 ± 6.19
22.17 ± 7.00
26.93 ± 2.84
55.62 ± 10.17

EDV = end-diastolic volume; ESV = end-systolic volume; SV = stroke volume; EF = ejection fraction.
All values are expressed as the mean ± standard deviation.
*significant

increase (p < 0.05) within group; †significant increase (p < 0.05) between groups; ‡significant increase (p
< 0.005) within group and also between groups at the same time point; §significant decrease (p < 0.005) within group
Note that for micro-CT measurements, n = 4 for mdx:utrn-/- mice as one mouse died before its scheduled 15-17 week
scan and as such was excluded from analyses

Table 3.1 Summary of M-mode, 3DE, and micro-CT measurements of cardiac
functional parameters.
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Figure 3.3 Progression of cardiomyopathy in mdx:utrn-/- mice. Cardiac functional
parameters were measured in wild-type and mdx:utrn-/- mice using 3DE and micro-CT.
Abscissa: time point; ordinate: mean measurement ± SD. Values measured through
micro-CT are shown for reference only. According to 3DE measurements, EDV and ESV
were significantly higher between 6-8 weeks and 15-17 weeks in both wild-type and
mdx:utrn-/- mice (*p < 0.05). EDV was significantly higher in wild-type mice at both time
points (**p < 0.05). Moreover, healthy mice had a significantly higher SV (†p < 0.005) at
15-17 weeks compared to baseline. These mice also had a significantly higher SV (†p <
0.005) than aged mdx:utrn-/- mice. The 15-17 week old mdx:utrn-/- mice also showed a
significantly decreased EF (†p < 0.005) compared to baseline.
Upon analysis of 3DE measurements, EDV and ESV were found to be significantly
increased (average EDV by 40.32%, average ESV by 54.47%, p < 0.05) by 15-17 weeks
in both wild-type and mdx:utrn-/- mice. Furthermore, overall, EDV was found to be
significantly higher (37.41%, p < 0.05) in wild-type mice than in mdx:utrn-/- mice; this is
likely correlated to the increased size and weight of wild-type animals compared to
dystrophic mice. More importantly, a significant interaction (p < 0.05) was found
between age and disease state for SV and EF. Post-hoc analysis revealed that healthy
mice had a significantly higher SV (47.68%, p < 0.005) at the 15-17 week time point
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compared to the 6-8 week time point. These mice also had a significantly higher SV
(58.81%, p < 0.005) than mdx:utrn-/- mice of the same age. No other significant
differences in SV were found. This indicates that stroke volume in mdx:utrn-/- mice does
not increase as the mice age, compared to healthy mice where the SV does increase. The
post-hoc analysis also revealed a significant decrease in EF (22.70%, p < 0.005) for 1517 week old mdx:utrn-/- mice as compared to 6-8 week old mdx:utrn-/- mice. No other
groups were significantly different. This shows that as mdx:utrn-/- mice age, they
experience a decrease in ejection fraction, while this is not observed in wild-type mice.

3.1.4

Fibrosis and Cardiomyocyte Hypertrophy in mdx:utrn-/- Mice

Lastly, cardiomyopathy was confirmed histologically. While control mice showed little
presence of fibrosis at either time point (0.01% and 0.9%, respectively), mdx:utrn-/- mice
displayed an increase in fibrotic tissue from 1.1% of total area to 2.5% over the course of
the study (p < 0.05; Figure 3.4).

Figure 3.4 Fibrosis in the mdx:utrn-/- myocardium. a) Quantification of collagen
staining is presented as % fibrosis of total myocardium + SEM. Aged mdx:utrn-/- mice
showed significantly higher fibrosis than all other groups (*p < 0.05). b) Masson’s
trichrome staining in wild-type (WT) and mdx:utrn-/- heart tissue at baseline and
termination. Collagen is indicated by areas stained in blue (arrows). Bar = 50μm.
Furthermore, the average cardiomyocyte area was significantly different between young
and aged mice (17.05% increase in size by 15-17 weeks, p < 0.01; Figure 3.5a), and
mdx:utrn-/- mice showed a significantly higher cardiomyocyte area than wild-type mice at
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both time points (21.23%, p < 0.005), indicating the presence of cardiomyocyte
hypertrophy (Figure 3.5b).

Figure 3.5 Hypertrophy in the mdx:utrn-/- myocardium. a) Average cardiomyocyte
area is presented in μm2. Both mice showed significantly increased cardiomyocyte size at
15-17 weeks of age, and mdx:utrn-/- mice showed larger cells than wild-type mice.
†
significant difference between age groups (p < 0.01); ‡significant difference between
mdx:utrn-/- and wild-type mice (p < 0.005). b) Hematoxylin and eosin staining of cardiac
tissue. Note the enlarged cardiomyocytes in the aged mdx:utrn-/- mouse. Bar = 50μm.

3.2

Characterization of Sca-1+ Cardiac Stem Cells

The next goal was to isolate and culture a population of Sca-1+ CSCs from healthy donor
mice via fluorescence-activated cell sorting (FACS), and subsequently characterize them
in vitro in order to determine their growth and differentiation capacity.

3.2.1

Cardiac Marker Expression in Sca-1+ CSCs PostDifferentiation

On average, FACS yield was 4×104 Sca-1+ cells, from 4-5 hearts, per sort. Upon plating,
the CSCs took around 3-5 days in culture to adhere to the bottom of the growth chamber
(Figure 3.6a). Cells reached confluency by 2-3 weeks (Figure 3.6b); at this point, the cells
were placed in low serum, dimethyl sulfoxide (DMSO)-based differentiation medium and
observed. No substantial differences in shape or viability were initially seen. However,
cell growth decreased noticeably, and after a few days, their morphology began to
change, with some cells appearing to take on a rod-shaped cytoplasm (Figure 3.6c). This
trend continued as the cells progressed through day 10 post-differentiation (Figure 3.6d).
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Figure 3.6 CSC microscopy. Representative phase contrast micrographs of live cardiac
stem cells (CSCs) in culture. Images were obtained at 20× magnification. a) Early-stage
adherent CSCs (4 days in culture). b) Upon contact with one another, the cells grew more
readily and their morphology became more heterogeneous. Confluency was reached
around 2-3 weeks in culture. c) CSCs at 4 days post-differentiation. Although the
morphology was still heterogeneous, the cells began to form extended, rod-like shapes
(arrows). d) After 10 days in differentiation medium, more cells took on the elongated
shape. Bar = 50μm.
Fluorescence immunocytochemistry was then performed. At day 4, differentiating CSCs
began to show signs of αMHC and cTnT expression, albeit in an unorganized and diffuse
manner (Figure 3.7a,c). Cx43 was also expressed to some extent just outside of the
nucleus, but also within some of the appendages extending from the cells (Figure 3.7e).
By day 10, as differentiation progressed, the proteins seemed to take on a more organized
appearance; αMHC was found localized in long cells and appendages (Figure 3.7b,f), and
while Cx43 was still expressed outside the nucleus, it was found to organize along the
cellular membrane. Overall, about 5-10% of cells expressed cardiac markers by day 10.
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Figure 3.7 Cardiac marker expression in differentiating CSCs. Fluorescence
immunocytochemistry analysis shows the expression patterns of connexin 43 (Cx43),
myosin heavy chain alpha (αMHC), and cardiac troponin T (cTnT) in cardiac stem cells
(CSCs) at a,c,e) day 4, and b,d,f) day 10 post-differentiation. Markers are indicated on
each micrograph in colour; nuclei of day 4 cells were stained with Hoechst. At day 4,
some cells begin to show diffuse expression of αMHC (a) and cTnT (c), while Cx43
starts to appear in some of the cellular appendages (e, arrowheads). However, by day 10,
cells show evidence of Cx43 expression along the cellular membrane (arrowheads),
indicating possible gap junction formation. Some organization of αMHC is evident in the
cellular appendages (arrows). Bar = 10μm.
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3.3 Closed-Chest Injections into the Left Ventricular
Myocardium In Vivo
In order to make a cell implant study feasible, an effective method of delivering the cells
to the myocardium was needed. To this end, a minimally-invasive closed-chest,
ultrasound-guided injection method was implemented. Pilot studies were conducted in
order to develop the basis of the technique that would ultimately be used to deliver stem
cells to the mdx:utrn-/- left ventricular myocardium.

3.3.1

Accuracy, Effectiveness, and Safeness of UltrasoundGuided Injection

To determine the effectiveness of method at delivering injectables to the target site,
healthy C57BL/6 mice (n = 3) were injected with 10μL of a saline solution containing
0.1% bromophenol blue dye and MicroMarker. Representative real-time ultrasound
images depicting the injection can be found in Figure 3.8. Furthermore, to ease
interpretation of the images and provide a truly detailed illustration, a video clip depicting
the injection is provided in Supplementary Material 3.1. The microbubble contrast agent
evidently helped confirm the accurate injection of the bolus in real-time and also served
to alert the sonographer of any leakage into the ventricle or thorax. After the needle was
retracted from the myocardium, the bolus remained within the myocardium, appearing as
a bright accumulation on the sonogram.
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Figure 3.8 Real-time confirmation of ultrasound-guided injection. Representative
images of ultrasound guidance process and the use of MicroMarker microbubble contrast
agent to confirm injection in real-time. The site of injection is indicated with a blue
arrow. a) The needle tip (blue arrowhead) was aimed towards its target, the midanterior/septal myocardium; b) once aligned, it was carefully advanced into the heart
wall. c) The bolus was then slowly injected; it appeared as a bright mass around the
needle tip on the sonogram. d) After injection, the needle was retracted from the
myocardium. The bolus is still visible within the beating heart wall. The ventricle
remained dark, indicating no leakage of the solution into the circulating blood. Bar =
2mm. For a better illustration of the injection, please see Supplementary Material 3.1.
Immediately after the injection was confirmed in real time, the mice were euthanized
under anaesthesia and their chest cavities were carefully opened. Visual inspection
revealed no substantial acute trauma to the liver, lungs, or diaphragm as a result of the
injections (data not shown). The hearts were then excised and examined for accumulation
of blue dye. As is evident from Figure 3.9, all three implants were successful, targeted the
mid-anterior/septal wall, and lacked any major indication of dye leakage from the
myocardium.
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Figure 3.9 Ultrasound-guided test injections of dye into the left ventricular
myocardium. 10μL of a 0.1% bromophenol blue solution was injected into the left
ventricular myocardia of three mice under ultrasound guidance. Hearts were subsequently
excised and analyzed for the presence of dye. a) The heart excised from Mouse A shows
clear evidence of a successful injection into the heart wall (arrowhead). The point of
entry of the needle is also evident in the pericardium (arrow). The heart chambers are
denoted (RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle). b)
While an entry point is visible in the heart from Mouse B (arrow), no distinct
accumulation of bromophenol blue is evident; c) however, when the heart was cut
transversely, the bolus became visible (arrowhead) in both the apical and basal halves. d)
The heart from Mouse C shows both a clear entry point (arrow) and a streak of dye
(arrowheads), possibly indicating a needle track; e) upon transverse sectioning, the bolus
(arrowhead) indicates the injection correctly targeted the mid-anterior/septal wall. No
substantial signs of acute leakage are present in any of the hearts. Bar = 1mm.
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To ensure animals were not adversely affected by the injection procedure proper, healthy
7-week-old C57BL/6 mice (n = 3) were injected with 10% MicroMarker in saline. Mice
A and B received a single 10μL bolus at a single location within the heart wall, while
Mouse C received four consecutive injections of 10μL each at different locations of the
heart. The mice were monitored and weighed prior to the injections, the day after, and
subsequently every other day for two weeks post-injection to assess physiological effects.
The results are presented in Figure 3.10. A very slight drop in weight occurred in all three
mice at Day 1. However, while mouse weights fluctuated from day-to-day, no substantial,
continuous drops in weight were evident. In fact, all of the mice grew in size and weight
by the end of the two week window. Surprisingly, Mouse C, which received four
injections, showed the greatest increase in weight from baseline (2.7g). Apart from
weight, the mice appeared healthy and active even on Day 1 post-injection, despite the
small drop in mass. No signs of lethargy, piloerection, lack of appetite, or lack of thirst
were observed.

Figure 3.10 Effect of closed-chest injection on mouse thrivability. Three healthy
mice were injected with contrast solution in order to gauge whether the ultrasound-guided
injection procedure was harmful to them. The mice were weighed and monitored every
other day for two weeks post-injection. Their weights are presented above, which each
mouse represented by a separate line. Abscissa: day of weighing; ordinate: weight. As is
evident from the graph, while the weights of the mice fluctuated to some degree, all three
mice consistently gained weight as they grew and thrived post-injection. Mouse C, which
received four injections, showed the greatest weight gain from baseline.
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3.4 Effects of CSC Implant on Systolic Function in
mdx:utrn-/- Mice
The ultimate goal of this project was to determine what effects, if any, transplanted
cardiac stem cells (CSCs) may have on cardiac function. For this purpose, the
methodologies described in the previous sections were jointly used.

3.4.1

Cardiac Function in Response to Sca-1+ CSCs

A pilot study was conducted to shed light on the possible effects of Sca-1+ CSC treatment
on systolic function in dystrophic mice. The cells were FACS-isolated as before, and
were implanted into mdx:utrn-/- mice via ultrasound-guided injection. 3DE was then used
to assess cardiac function. The optimal control for this type of experiment would have
been sham-injected mice; however, in the current situation, assessing such a treatment
was not a possibility. While great effort was put forth to obtain a sample size of at least n
= 5 for each of the cell-injected and sham-injected groups, due to breeding difficulties,
small litter sizes, and the inherent fragility of these animals leading to premature death,
only 2 mdx:utrn-/- mice successfully completed this study. Both were assigned to the CSC
treatment group. As such, to determine any possible therapeutic effects derived from stem
cell treatment, the measurements obtained from implanted mice were directly compared
to those from the cohort of untreated mdx:utrn-/- mice used in the 3DE/micro-CT study
(4.1.2). Despite not receiving sham injections, it was reasoned that these mice would be
the best available control for the current early-stage study.
The mdx:utrn-/- mice in the treatment group (n = 2) each received a cell dose of 1×104
CSCs. This therapeutic dosage is in the low range of cell numbers administered relative
to previous studies50,75,162–166; a smaller dosage was chosen based on the yield of CSCs
from FACS isolation, and because it was expected to be less harsh on the fragile
dystrophic mice. Treated Mouse A received cell injection at 7 weeks of age, while Mouse
B received injection at 4 weeks of age. Baseline 3DE scans were performed immediately
prior to cell injection while endpoint scans were performed at least 5 weeks post-implant,
as this is considered the minimum time required for stem cells to have a regenerative
effect93. Endpoint was ultimately determined by the onset of substantial skeletal/smooth
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muscle deterioration, manifested as lethargy and breathing difficulty. In Mouse A, this
occurred at 16 weeks, whereas in Mouse B, it occurred at 9 weeks. The results from both
of these mice are presented against untreated controls in Figure 3.11. No statistical
analysis could be performed on the data due to the small sample size, and as such, no
definitive effects can be inferred. Nevertheless, certain trends can be observed from the
data. In Mouse A, which was larger in size and lived to an older age than Mouse B, EDV
increased by endpoint much in the same way it did for controls. However, while ESV
showed a substantial increase in untreated mice, the change was not as drastic in Mouse
A. This translated to an increase in SV by endpoint, which led to smaller changes in
ejection fraction compared to controls. On the other hand, the smaller Mouse B showed
little change in both EDV and ESV compared to untreated animals. This meant that SV
changed very little by endpoint. As such, ejection fraction in this mouse again did not
change as drastically as it did in the controls.

Figure 3.11 Preliminary systolic function data from CSC-treated dystrophic mice.
Cardiac stem cells (CSCs) were implanted into mdx:utrn-/- mice and cardiac function was
monitored before implant and at least 5 weeks post-implant. Treated mice (n = 2) are
respectively shown in gray and black. By endpoint, treated Mouse A exhibited a smaller
increase in ESV compared to controls, which ultimately translated to an increased SV and
only slightly decreased EF by endpoint. Mouse B showed little change EDV, ESV, and
SV, and as such, EF did not drastically decrease as it did in the controls. The high degree
of variability in the two mice can be explained by their varied size and weight.
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4

Discussion and Future Directions

Duchenne muscular dystrophy (DMD) is a serious genetic neuromuscular disease which
has a devastating impact on many young patients. Although clinical intervention has
allowed the management of the skeletal muscle and diaphragmatic manifestations of
DMD, treatments targeting the characteristic dilated cardiomyopathy have been
unsuccessful, and no cure exists. This dissertation sought to investigate a novel subtype
of stem cell antigen 1 (Sca-1)-expressing cardiac stem cells (CSCs), and determine what
regenerative effects they have in a mouse model of DMD. Briefly, the main objectives
were: 1) to validate and implement a three-dimensional echocardiography (3DE) method
to assess cardiac systolic function in the mdx:utrn-/- double-knockout model of DMD; 2)
to isolate a population of Sca-1+ CSCs from healthy mice and investigate their potential
to differentiate down the cardiomyocyte lineage; 3) to implement a closed-chest
ultrasound-guided injection method of delivering therapeutic agents directly to the
injured myocardium and corroborate previous evidence indicating its usefulness; and 4)
after accomplishing the aforementioned goals, to implant Sca-1+ CSCs into the heart
walls of young mdx:utrn-/- mice and examine any changes that may have occurred in
terms of cardiac function.

4.1 Assessment of Cardiac Function in mdx:utrn-/- Mice
via 3D Echocardiography
In this study, the ability of non-invasive, prospectively-gated 3DE to quantitatively assess
the development of dilated cardiomyopathy in the mdx:utrn-/- mouse model of DMD, and
its accuracy in doing so, were investigated. This was proposed as an alternative to the
current standard echocardiographic method of assessing cardiac function in mice, which
involves taking motion mode (M-mode) images and applying the Teichholz correction
formula to linear measurements; this practice may be problematic because of the inherent
and necessary assumptions for heart shape, which may lead to inaccuracies in the data.

4.1.1

3DE is More Accurate and Less Variable than M-mode

The results of this study support the validity of 3DE as a reliable method of assessing
cardiomyopathy in mdx:utrn-/- mice and as a quick and cost-effective alternative to M-
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mode. Compared with a gold-standard method, retrospectively gated cardiac microcomputed tomography (micro-CT), 3DE showed less bias and greater agreement with
micro-CT measurements, suggesting it is more accurate than M-mode. It also showed less
variability between multiple measurements than did the M-Mode method, which may
translate to less user variability. The high reproducibility and small variability offered by
3DE over M-mode echocardiography will allow the use of the method for longitudinal
studies, in which highly accurate measurements of cardiac function can be easily taken at
multiple time points throughout the life of the dystrophic mouse.
The present study is the first of its kind to correlate cardiac volumes and ventricular
function in dilated cardiomyopathy acquired using 3DE with those acquired using
another 3D imaging technology, namely, retrospectively gated micro-CT. Although 3DE
necessitates more time and user input for scanning and analysis (around 30 minutes total
time per scan, 15 minutes for volume segmentation), it proves to be more accurate than
traditional M-mode echocardiography and circumvents the use of radiation and contrast
agents, which can be potentially dangerous to the fragile mdx:utrn-/- mice and stem cells.
3DE also requires less training on the part of the researcher, and it shares the costeffectiveness of M-mode while providing a truly volumetric method of evaluation.

4.1.2

Systolic Function is Reduced in mdx:utrn-/- Mice

Once the validity of 3DE was determined, it was then used to assess cardiac function and
the development of dilated cardiomyopathy in the mdx:utrn-/- mouse model of DMD.
Although the data show that both healthy and dystrophic mice exhibit larger end-diastolic
and end-systolic volumes as they age (further evident in Figure 2.4), healthy mice have a
significantly higher stroke volume at 15-17 weeks of age, which translates into a larger
volume of blood pumped out per heartbeat. This is to be expected, because as the mice
age, the heart will have to pump a higher volume of blood around the body. In contrast,
mdx:utrn-/- dystrophic mice exhibited no increase in stroke volume as they age. This
ultimately translated to a significantly decreased ejection fraction compared to 6-8-weekold mdx:utrn-/- mice, indicating that cardiac function in these mice was greatly hindered
over time. These findings corresponded to histological analysis of cardiac tissue from
both healthy and dystrophic mice, wherein Masson’s trichrome staining revealed
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significant fibrosis in hearts of 15-17-week-old mdx:utrn-/- mice as compared to all other
groups. Indeed, it is also evident from Figure 3.4 that young mdx:utrn-/- mice exhibit
roughly the same degree of fibrosis as aged controls. These results further corroborate the
idea that the double-knockout model provides an apt representation of the fibrotic
progression present in DMD40. Furthermore, although both mouse groups exhibited
increased cardiomyocyte size by 15-17 weeks, the dystrophic mice had significantly
larger cardiomyocytes compared to controls at both time points, illustrating the
hypertrophy and increased muscle mass characteristic of their phenotype59. Together,
these observations support the notion that the mdx:utrn-/- mouse develops a clinically
relevant form of cardiomyopathy in the later stages of its life. Because cardiomyopathy
arises much earlier in these mice than in the ubiquitous mdx model, they are much more
valuable to cardiac function studies, and as such, are a reliable model of DMD and
dilated cardiomyopathy.
Understanding the cardiomyopathy process first in pre-clinical small animal models of
DMD, and subsequently in young patients before the development of overt
cardiomyopathy, may later provide us with unique opportunities for the early detection of
heart disease in other patient populations—for instance, in idiopathic populations,
wherein the development of dilated cardiomyopathy is not certain. Many groups now
report the use of echocardiography to measure changes in cardiac output/ventricular
function in mice; nonetheless, most of these studies assess such changes in models of
ischemic cardiomyopathy123,134,167. To date, DMD animal models, including the mdx and
mdx:utrn-/- mouse models, are some of the only models of dilated, non-ischemic
cardiomyopathy44; hence, there is a great need for the characterization of disease
development/progression in these mice. This study suggests that the use of 3DE over
standard M-mode will allow for increased sensitivity to detect subtle early changes in the
development of dilated cardiomyopathy that occur before gross changes are evident.
Moreover, 3DE will be useful to accurately assess the effects of treatments in mice.

4.2

Characterization of Sca-1+ Cardiac Stem Cells

After establishing the accuracy and utility of 3DE in determining small changes in
systolic function, the effects of CSCs on DMD-related cardiomyopathy were sought to be
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investigated. For this purpose, a population of Sca-1+ CSCs needed to be characterized;
these cells were expected to successfully grow and differentiate in vitro, expressing
protein markers typical of cardiomyocytes.

4.2.1

Isolation of Sca-1+ CSCs

While it is also a marker of multipotent hematopoietic stem cells in mice, the
phospatidylinositol-anchored protein Sca-1 has been used to enrich for stem and
progenitor cell populations in other non-hematopoietic tissues168. In this study,
fluorescence-activated cell sorting (FACS) was used to purify a population of CSCs that
expressed Sca-1. The isolated Sca-1+ CSC population was negative for other endothelial
and hematopoietic progenitor cell markers, postulating the notion of a purified CSC
subtype109. Overall, cell yield was around 4×104 per sort, obtained from 4-5 mice. This
was not unexpected, as the population is relatively rare under normal conditions in
mice105, and so is the orthologous Sca-1+ CSC population in humans112. As a point of
comparison, the remainder of non-Sca-1+ cells counted during the sorts was generally in
the order of 2×106 cells. This was likely composed of cardiac myocytes, cardiac
myoblasts, and other subtypes of CSCs. Thus, the Sca-1+ population represented about
2% of the total cells, which is on par with previous reports106,107,109,111.
In vitro primary cardiac myocyte/myoblast culture has been a very fruitful undertaking in
modern labs as it complements mouse models of cardiovascular disease; it is particularly
useful for studying changes in CSCs at the molecular level, especially in ion homeostasis
and excitation-contraction coupling109,169. Although cells have been sourced from both
humans and animals of varying ages, most groups study neonatal cardiomyocytes largely
derived from rats170–173. The isolation process generally involves excising the heart from
euthanized animals, digesting the connective tissue by a combination of physical and
enzymatic means, performing a crude enrichment for cardiomyocytes with different
growth media, and finally propagating and studying the cells86,106,110,155,174. However,
neonatal cardiomyocytes lack many structural and functional characteristics of adult
cardiomyocytes, and disease models are much more readily available in mice, which may
make them more appealing than rats as a source for primary cardiomyocytes169. In this
study, the process by which adult cardiac stem cells of murine origin were obtained is
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superior to more commonly used methods; stringent selection based on an array of
surface markers allows for the isolation of specific populations with high purity, without
the need for timely media cycling.
As the Sca-1+ population studied here was very specific and requires high purity, the
FACS approach was ideal. However, the main compromise and disadvantage to this
method was that cell yield was relatively low compared to what would have been
obtained with other, less-specific isolation procedures. This has important connotations
when considering the stage at which CSCs should be implanted: freshly sorted, or
propagated in culture. Indeed, there is much debate on this topic, and the protocols of
various labs differ on this issue7,107,110,163–165. Although the optimal number of CSCs
required to elicit an effect is still uncertain7, one may not be implanting sufficient
numbers of cells if using the freshly-sorted approach. Future studies should investigate
and determine at which of the two stages Sca-1+ CSCs exhibit the greatest degree of
functional improvement post-implant.

4.2.2

Evidence of Cardiac Marker Expression in Sca-1+ CSCs
Post-Differentiation

After isolation, the Sca-1+ CSCs were seeded onto tissue culture plates, to which the cells
noticeably adhered after 3-5 days; this was again to be expected, as primary cardiac stem
cells are documented to require upwards of 12-24 hours to become adherent171. They
were then successfully expanded in culture, reaching confluency after 2-3 weeks. Their
growth rate in culture increased with cell density, which is on par with previous reports of
CSC culture98. After reaching confluency, the cells were cultured in differentiation
medium containing dimethyl sulfoxide (DMSO) for up to 10 days.
At days 4 and 10 post-differentiation, representative samples of cells were probed for
three proteins: myosin heavy chain alpha (αMHC), one of six subunits in the myosin
contractile complex within the cardiomyocyte sarcomere; cardiac troponin T (cTnT), one
of three proteins in the troponin complex responsible for regulating contraction; and
connexin 43 (Cx43), the main gap junction protein in ventricular myocardium, which
ultimately allows for intercellular communication and the transmission of action
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potentials175. Differentiating CSCs began to show expression of all three markers as early
as day 4. However, their expression patterns were unorganized and diffuse—all proteins
were found largely unstructured in the cytoplasm. This may indicate that, at this stage of
differentiation, the cells were just beginning to commit to the cardiac lineage and
beginning to express the proteins, which were observed in an immature state. Some Cx43
expression was found within cellular appendages, which may indicate it is being
transported to its final location, the cellular membrane. This is further supported by cells
probed at day 10, which show expression of Cx43 organized along the membrane.
Although expression is relatively low, it could point to the formation of early gap
junctions. Interestingly, Cx43 was found to be localized around the nucleus in all of the
cells tested. It was proposed that this is indicative of Cx43 being transcribed and
processed within the endoplasmic reticulum; indeed, other groups probing stem cells with
the same antibody used here have observed similar results50. Moreover, at day 10, αMHC
began to take on a more organized appearance, appearing to congregate within the
appendages observed in differentiating cells. This further supports the notion that the
appendages may later produce troponin- and myosin-rich striations.
Taken together, the results provided here support the hypothesis that cardiac stem cells
can be isolated from adult murine heart. Nevertheless, at the two stages of differentiation
analyzed, all markers appeared relatively unorganized and immature. Even so, only
around 5-10% of total cells expressed cardiac markers by day 10, and no beating
phenotype was observed. This low efficiency of differentiation may have come as a result
of day 10 being too early along the timeline of differentiation for these cells. Moreover,
the in vitro differentiation system used here inherently does not capture the subtle
nuances of paracrine signalling that are characteristic of in vivo differentiation. DMSO
was chosen as a differentiation agent due to its DNA-demethylating characteristics and
ease of use176; this agent is widely reported to unmask seldom-expressed genes and
promote differentiation in embryonic stem cells (ESCs) and mouse embryocarcinoma
cells, where it produces a cardiomyocyte-like beating phenotype177–182 and expression of
cardiac markers, including GATA4 and Nkx-2.5183,184. However, DMSO-mediated
differentiation of cells into cardiomyocytes is known to be relatively inefficient181,185. A
simple alternative is the use of 5-azacytidine (5-aza), another demethylation agent186. It

65

has also been widely documented to induce differentiation in both ESCs and CSCs, being
highly efficient at producing beating cardiomyocytes77,107,112,179,182. Nevertheless, the use
of such an agent is still not an accurate reflection of in vivo paracrine signalling. Future
studies focusing on emulating this type of environment would be very interesting, and
may help produce a truly accurate representation of these cells’ cardiomyogenic potential.
Previous reports have indicated that adult ventricular cardiomyocytes are resistant to cell
cycle re-entry due to their lack of telomerase activity; for this reason, it has been
suggested that these adult cells do not play a large role in repair during cardiac tissue
injury187. Sca-1+ CSCs are a potential source of regeneration during injury, but their
ability for endogenous cardiac repair is largely unknown. Thus, in the present study, a
population of Sca-1+ CSCs was isolated and evidenced to differentiate along a cardiacspecific lineage.

4.3 Closed-Chest Injections into the Left Ventricular
Myocardium In Vivo
After characterizing the Sca-1+ CSCs, the next goal of this dissertation was to implement
a closed-chest method of implant to deliver them to the mdx:utrn-/- myocardia. For this
purpose, test studies were carried out using a minimally-invasive, ultrasound-guided
needle technique to deliver therapeutic agents directly into the live left ventricular
myocardium of mice. This method circumvents the need for complicated thoracotomy
procedures, while also being a timely and highly repeatable procedure well-suited for
fragile mdx:utrn-/- mice. The method was expected to be accurate at targeting regions in
the left ventricular myocardium and effective at maintaining the injected bolus there.

4.3.1

Ultrasound-Guided Injection is Accurate, Effective, and Safe

Test injections were carried out using healthy mice as recipients of the injections. These
mice were chosen due to their being readily available and more able to withstand possible
complications that may have arisen from the injection process. Real-time analysis of the
sonogram allowed for the confirmation of the injection into the myocardium by way of
bright contrast visualization. This highlighted the two main advantages of this technique:
firstly, that visualization of the needle within the thoracic cavity allows one to target
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specific regions of the myocardium for injection; and secondly, that usage of hyperechoic
contrast helps to assess the injection of the bolus within the myocardium, immediately
alerting the sonographer to any leakage into the ventricle or into the thoracic cavity. As a
control, very early tests showed that deliberate injection directly into the ventricle caused
the blood pool to immediately appear bright on the sonogram, even with minuscule
amounts of contrast agents. The ability of this technique to show leakage into the
ventricle will be key to troubleshoot future experiments in real-time. This is impossible
using classic thoracotomy, as the person delivering the injection is somewhat blind to the
depth of the needle tip once it is in the myocardium, and the thickness of the heart wall
(1-2mm) makes it easy to over- or under-shoot. Furthermore, the only way to determine
the occurrence of leakage in this case is post-mortem.
After injections were confirmed in real-time, mice were sacrificed and their hearts
excised. In all three hearts examined, the bolus was clearly contained within the
myocardial wall as indicated by localized concentration of bromophenol blue dye, and
showed no signs of leakage on either facet of the myocardial wall. If leakage had indeed
occurred, clear blue areas would have been visible. Moreover, examination of the bolus
location provided definitive evidence that the technique was accurate in targeting the
injection to the middle of the anterior-septal myocardium, providing proof-of-concept for
ultrasound targeting.
A study using healthy mice was performed to fully ensure the guided injection itself
produced no substantial harm to the animals. The method again proved exceptional in this
respect, with young mice gaining healthy weight over the two weeks following implant.
It came as a surprise that Mouse C, which received a total of four injections, had the
greatest degree of weight gain; this is very promising for future studies wherein cells may
need to be delivered to multiple regions of the myocardium. Indeed, these results were to
be expected, as this method is far less invasive than common thoracotomy procedures.
The next logical step for future validation studies is to perform test implants using cells:
firstly, to determine whether they are detectable histologically post-implant, and based on
this, to determine the degree of cell retention within the myocardium at various time
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points post-implant. For these studies, the cells should be labelled with a fluorescent
marker (e.g. DiI), or should express some type of reporter [(e.g. green fluorescent protein
(GFP)], which will allow their subsequent detection by immunohistological analysis.
Implanted cells are also expected to be located as a concentrated amalgamation of nuclei
within the tissue, while healthy cardiomyocytes should be readily distinguishable from
the host tissue via their expression of dystrophin. Moreover, as is evident in Figure 3.9,
the injection method kept the bolus tightly concentrated within the myocardial wall. As
such, to avoid superfluous tissue sectioning in the future, the bolus should contain some
type of visual marker (e.g. coloured dye or microbeads), which is safe for the mouse in
the long term, and will also allow for gross localization of the injectate during embedding
and sectioning. This will greatly help in orienting the histologist to the site of the
injection, and will ensure that this region is aptly probed for the presence of cells.
Another interesting strategy is to engineer the cells to express a protein that sequesters a
certain substrate. Subsequently, a given time after injection, one may inject the substrate
systemically and perform biodistribution analysis to evaluate the relative quantities of
cells within the injected site, and perhaps determine how much of the bolus was lost from
the target. This may also be applicable in future stem cell studies to determine the amount
of neo-angiogenesis and migration ability of cells.
These results show great promise for the ultrasound-guided injection method. However,
as with any procedure, this method is not without its limitations. There will be an
inherent learning curve for any untrained sonographer starting to use the method, and
moreover, a steady hand is required to maneuver the needle using the injection arm.
Scientists wishing to implement this technique in their research should take due time to
train themselves in using it prior to any attempting any experiments. Furthermore, one of
the key players in the success seen here was the sickle-shaped needle. Preliminary
injections were performed using regularly-bevelled needles, which were found to easily
leak excessive injectate into the ventricle as a result of piercing through the endocardium.
The advantages of the special tip are thus clear, but come at the compromise of cost.
Despite these limitations, overall, the results presented here are on-par with findings from
the only other group reported to perform intra-myocardial (IMC) injections under
ultrasound guidance in mice43,145,146, which is testament to the strengths of the
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methodology. Through the use of a higher-resolution ultrasound scanner, specialized
needle, and a preclinical contrast agent, the method used here presents advances that will
greatly benefit future therapeutic experiments.

4.4 Effects of CSC therapy on Systolic Function in
mdx:utrn-/- Mice
Once the ultrasound-guided injection method was shown to be successful at delivering
and maintaining a bolus locally within the myocardium in vivo, it was deemed suitable
for use in preliminary Sca-1+ CSC studies with mdx:utrn-/- mice. Importantly, this
procedure was not only expected to produce accurate delivery of the stem cells, but also
to be less strenuous on the fragile mdx:utrn-/- mice. These animals were expected to show
a smaller decrease in systolic functions than untreated controls.

4.4.1

Preliminary Evidence of Functional Improvement

Despite the small sample size, the results presented here indicate functional improvement
in the CSC-treated mdx:utrn-/- mice, as evidenced by 3DE. Specifically, while EDV and
ESV increased in both groups by endpoint, the increase in CSC-treated mice was less
severe than in untreated controls. This may be indicative of the treatment ameliorating the
dilated phenotype in these animals. SV also showed an increase in Treated Mouse A by
endpoint, which is reflective of the situation in healthy animals. Perhaps most
intriguingly, neither of the treated mice showed the substantial decline in EF
characteristic of the mdx:utrn-/- strain and exhibited by the controls. These results may
indicate that Sca-1+ CSC treatment potentially slowed the progression of dilated
cardiomyopathy in these animals.
Nevertheless, as this was a very preliminary study, certain limitations have to be
considered. Firstly, the sample size obtained for the treatment group was insufficient,
meaning true statistical analysis was not possible. Furthermore, the optimal negative
control for cell injection would have been a sham-treated group, which was not possible
for the aforementioned reason. Ideally, and with due time, sufficient animals will be
acquired for both groups, and the data obtained from them will be analyzed using a twoway mixed-design multivariate analysis of variance with Tukey’s post-hoc test.
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Furthermore, as is evident from Figure 3.11, the two treated animals differed greatly in
the measured parameters. This came as a result of their differing sizes and weights:
Treated Mouse A was larger and heavier than Treated Mouse B. In the future, once
optimal sample sizes are obtained, variability between the animals should be accounted
for and statistically removed from the data. One way to achieve this is through analysis of
covariance (ANCOVA), wherein mouse weight will be considered a confounding
variable and its effects on the measurements removed. This may further help to elucidate
small but significant differences in the data that would otherwise go unnoticed due to
variability. In addition, as mentioned previously, Treated Mouse A was scanned at an
endpoint of 9 weeks post-injection, whereas Treated Mouse B was scanned at 5 weeks
post-injection due to substantial weight loss. This supports the notion that the disease can
affect the animals differently based on their anatomy and physiology. Here, Mouse B
exhibited more severe kyphosis than Mouse A; as kyphosis is characteristic of this mouse
strain, it can serve as a rough indicator of disease progression and diaphragm function. As
is the case for patients, mdx:utrn-/- mice largely die as a result of severe respiratory
dysfunction, and perhaps this was the case for Mouse B. In future experiments, three
defined time points will be used to assess function: 5 weeks (baseline), 10 weeks
(intermediate), and 15 weeks (endpoint). This will provide a more robust basis for
statistical analysis and will allow for easier exclusion of mice that die prematurely.
Another aspect to consider in such a study is the number of cells implanted. As
mentioned previously, the cell dosage delivered here is relatively low compared to
previous reports50,75,107,162–166,188 due to the Sca-1+ CSC yield, and also to cells being
implanted immediately following isolation. It can be argued that the number of cells
implanted here may have been too low to elicit an optimal response. Previous work
showed that stem cells have a low retention once inside target tissues74,165; this may come
as a result of any number of factors, including cell death due to shear stress from the
needle, death due to injection-induced inflammation in the target site, and bolus leakage.
Thus, only a fraction of the total number of implanted cells may have been truly able to
elicit a regenerative effect. As discussed in 4.2.1, there is still debate in the field
regarding whether to implant freshly-sorted cells or cells propagated in culture. Given a
high enough sample size, future studies should investigate both of these possibilities, as
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the regenerative capacity of CSCs may differ depending on preparation. Once the
minimum number of implanted cells detectable by histology is confirmed, it will provide
a better indication as to the number of Sca-1+ CSCs that should be implanted into
dystrophic mice for therapeutic studies.
With this in mind, immunohistochemical analysis should also be performed in future
experiments to determine the presence of implanted cells, the degree of tissue
regeneration, the expression of cardiac markers, as well as any changes in fibrosis and
hypertrophy. Furthermore, the mechanism of Sca-1+-mediated regeneration should be
determined. Stem cells are generally known to migrate poorly post-implant into
muscle189, and as such it is theorized that the direct effect of cell transplantation is local.
Evidence also shows that endogenous Sca-1+ CSCs may have a reduced rate of
regeneration in diseased states105, but that autologous, transplanted Sca-1+ cells stimulate
endogenous CSCs and also promote neovascularization116. The current study did not
investigate whether the observed improvement was due to myocardial regeneration,
paracrine stimulation, or neovascularization; as such, future work should also determine
the paracrine or pro-angiogenic effects that Sca-1+ may have in mdx:utrn-/- myocardia.
These analyses will ultimately elucidate the true effect that these cells are having within
the injured mouse myocardium.
Ultimately, although statistical inference could not be incurred using the current data, it
presents promising results that provide impetus to continue exploring Sca-1+ CSC
therapy in future studies. As of yet, only a single study has been published investigating
any stem cell regenerative therapy for cardiomyopathy in mdx:utrn-/- mice; Chun et al.50
describe improvements in systolic function and expression of dystrophin as a result of
aorta-derived mesoangioblast treatment. These findings are very encouraging and have
important potential for future therapeutic application. However, as with any disease, it
should be approached from multiple angles, and autologous Sca-1+ CSCs may provide
certain advantages over non-cardiac-derived stem cells, which should be explored further.
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4.5

Future Directions

Importantly, the current study helped to produce valuable tools that will be indispensable
to pre-clinical DMD-related cardiomyopathy research, and also the delivery of treatment
in such studies. It would now be of particular interest to employ 3DE in assessing the
progression of cardiomyopathy in utrophin-heterozygous mice (mdx:utrn+/-). Due to their
genotype, they may prove to be a more accurate representation of DMD-related
cardiomyopathy than mdx mice, while also being more resilient than severely-affected
mdx:utrn-/- mice. Aside from 3D imaging, the Vevo 2100 system also allows for highquality Colour Doppler imaging, which can be used to assess blood flow directionality in
vessels and through valves—this may have the potential to determine the presence of
mitral valve regurgitation in mdx and mdx:utrn-/- mice, a phenomenon which is observed
in DMD patients25. One can also perform regional strain analysis using the Vevo system
to determine regional myocardial dysfunction121; this may elucidate valuable information
on regional fibrosis in these mice, which can help in targeting CSC treatment to the most
severely-affected areas of the heart. Indeed, echocardiography is actively used in the
clinic with DMD patients37, and this encourages further studies in mice using this
methodology.
Previous reports using nuclear medicine techniques in DMD patients have also uncovered
a reduction in myocardial perfusion, along with an increase in glucose metabolism within
cardiac muscle35,36. This was speculated to arise as a result of ischemia, one of the main
hallmarks of DMD40. In order to further elucidate changes in myocardial ischemia in
mdx:utrn-/- mice, it would be interesting to gauge these two functional parameters.
Previous work by our group has shown that non-invasive imaging using dynamic
contrast-enhanced computed tomography (DCE-CT) and micro-positron emission
tomography (μPET) can reliably detect changes in perfusion and glucose
uptake/inflammation in the skeletal muscle of mdx:utrn-/- mice15. Specifically, while
initial increases in both parameters were observed at 8 weeks of age, both significantly
decreased by 20 weeks compared to baseline and age-matched controls. Importantly,
these changes were reported to occur prior to a significant reduction in muscle contractile
function, and thus may predict end-stage DMD. As such, assessing myocardial perfusion
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and glucose metabolism non-invasively may also provide an important insight into the
mechanism of cardiomyopathy within mdx:utrn-/- mice, and to date, no studies have
explored this. For this purpose, myocardial perfusion will be assessed by DCE-CT in
mdx:utrn-/- mice, while myocardial metabolism and/or inflammation will be determined
by μPET imaging of the uptake of a radiolabelled glucose analog. Furthermore, if these
methods prove to be feasible, it would also be interesting to investigate these functional
parameters in cell-treated mice to ascertain the local growth and regenerative capacity of
the transplanted CSCs, and whether they have an anti-ischemic effect.
Furthermore, prospective studies may investigate the effects of co-administration of
certain factors with CSCs. For instance, a previous study has shown that c-Kit cells can
be stimulated to regenerate myocardium by treatment with insulin-like growth factor 1
(IGF-1) and hepatocyte growth factor (HGF)7, and others indicate that co-transplant of
CSCs with circulatory angiogenic stem cells may have a greater combined therapeutic
effect, as they act synergistically: one regenerates myocardium while the other
regenerates the vasculature74. These are intriguing ideas, since this kind of therapy may
be able to target DMD-related ischemia, inflammation, and fibrosis concomitantly, and so
far no studies have investigated Sca-1+ cells in this context.

4.6

Conclusions and Significance

In summary, this dissertation reported that 3DE correlates well with cardiac micro-CT in
the analysis of cardiac volume and cardiac output/ventricular function in mdx:utrn-/- mice
and, importantly, provides greater accuracy with less user bias/variability than standard
M-mode echocardiography. 3DE was then used to demonstrate the progression of
cardiomyopathy in mdx:utrn-/- mice. Subsequently, the ability of purified cardiac stem
cells to differentiate into cardiomyocytes in vitro was shown, as indicated by the
expression of cardiac-specific markers. The accuracy and attractiveness of closed-chest
ultrasound-guided injections were then demonstrated, and preliminary evidence of Sca-1+
CSC-mediated improvement of cardiac function was presented. These studies were
conducted in the order presented above and all built on each other; when used together,
they proved to be an indispensable set of tools for assessing cardiac function in, and
delivering treatment to, the dystrophic mouse heart.
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Although it is still largely in its infancy, regenerative stem cell therapy has the potential
to change the clinical landscape and significantly improve treatment outcome for patients
struggling with DMD and other cardiovascular diseases. However, before this can occur,
the exact processes behind their differentiation and mechanism of repair need to be
understood. Nevertheless, cell replacement therapy presents an appealing and sustainable
alternative to drug administration, and in the future, may curb the need for heart
replacement in patients with end-stage heart failure. Furthermore, it may prove to be an
excellent candidate for DMD patients, and may be the missing piece of the puzzle in
providing truly effective therapy for DMD-related cardiomyopathy. It is our hope that
stem cell therapy will abolish the inefficient treatments currently standard in clinics,
while greatly improving DMD survivability and quality of life.
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Appendix B. Ethics Approval for the Use of Animal
Subjects
-------- Original Message -------Subject: eSirius Notification - Annual Protocol Renewal APPROVED by the AUS 2008-067::5
Date: 2014-10-20 15:23
From: AUSPC <auspc@uwo.ca>
To: "'Lisa Hoffman'" <lhoffman@lawsonimaging.ca>

2008-067::5:
AUP NUMBER: 2008-067
AUP TITLE: Non-Invasive Imaging of Therapeutics in Mouse Models of DMD
YEARLY RENEWAL DATE: 12/01/2013
THE YEARLY RENEWAL TO ANIMAL USE PROTOCOL (AUP) 2008-067 HAS BEEN
APPROVED, AND WILL BE APPROVED FOR ONE YEAR FOLLOWING THE ABOVE REVIEW
DATE.
* This AUP number must be indicated when ordering animals for this project.
* Animals for other projects may not be ordered under this AUP number.
* Purchases of animals other than through this system must be cleared through the ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this
protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety
standards and have received all necessary approvals. Please consult directly with your
institutional safety officers.

Submitted by: Kinchlea, Will D

on behalf of the Animal Use Subcommittee
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